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ABSTRACT

This dissertation begins with the introduction of genetics, genomics, and the Healthcare
Genetics (HCG) model. The five concepts of the HCG model, genetics/genomics, education,
environment, clinical testing and therapeutics, and ethical/legal/social implications (ELSI) are
defined. These concepts are threaded throughout the manuscripts and dissertation chapters.
Chapter II defines molecular testing and differences between single-gene and multigene testing. The Kaplan Meier Curve and its use in research, to illustrate survival over time, is
discussed. The chapter provides specific examples of both predictive and prognostic genomic
testing used in breast, lung, colon, and prostate cancers.
Chapter III examines the application of the Theory of Planned Behavior (TPB) in
genomic nursing practice. The TPB constructs—attitude, subjective norms, and perceived
behavioral control—are described along with genomic research examples.

The chapter

concludes with three exemplars that illustrate the importance of genomic-competent care in
nursing practice.
Chapter IV presents a mixed-methods study that explored nurses’ use of genomics in
practice and identified barriers to genomic-competent care. The quantitative and qualitative
results found that gaps exist between genomic education and practice. The most commonly
cited barriers were a lack of knowledge, support, and costs.
Chapter V begins with a summary of the previous four chapters. Limitations are
described related to the content of Chapters I through III and the research study presented in
Chapter IV. Chapter V concludes with recommendations for future research based on this
dissertation.
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CHAPTER I
INTRODUCTION

Genomics is the study of genes collectively, including their interactions together
and with the environment (National Human Genome Research Institute (NHGRI), 2020).
Genomic research has gained momentum over the past two decades.

Genomic

knowledge, gained from the Human Genome Project (NHGRI, 2020), increased the
utilization of technology, expanded the employment of large data bases and
bioinformatics, and accelerated research development (Aiello, 2017; Shendure, Findlay,
& Snyder, 2019). As the largest group of health care professionals, it is imperative that
nursing professionals take responsibility to educate themselves, become competent, and
apply genomics in the care of patients and their families (Jenkins, 2019).
Watson and Crick (1953) first described DNA as a double helix in 1953 and
developed a model that is still in use (Pray, 2008).

Neonatal testing and prenatal

counseling have been a part of genomic nursing practice since the 1960s (DeLuca et al.,
2013). In 1997, the American Nurses Association recognized genetics as a nursing
specialty (International Society of Nurses in Genetics, 2007). The Scope and Standards
of Clinical Genetics Nursing was first published in 1998 by the International Society of
Nurses in Genetics (ISONG) and the American Nurses Association (ANA) (ISONG and
ANA, 1998).

This landmark document was followed by Scope and Standards of

Practice, Genetics/Genomics Nursing, 2nd edition, in 2016 (ISONG and ANA, 2016). In
addition, the Oncology Nurses Society (ONS) published scopes and standards of practice
guidelines in genomics for nurses (Lubejko and Wilson, 2019).
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As essential members of the healthcare team, nurse and advanced practice nurses
must be prepared to provide genomic competent care to patients and families, and to
guide the implementation of care that promotes optimal patient outcomes (Rogers et al.,
2017). In addition to the documents cited, three other seminal documents advanced
genetics and genomics in nursing education. The American Nurses Association (ANA)
published the Essentials of Genetic and Genomic Nursing: Competencies, Curricula
Guidelines, and Outcome Indicators (2nd ed.) in 2009 and was endorsed by 47 nursing
organizations. Genomics is also addressed in the American Association of Colleges of
Nursing (AACN) Essentials of Baccalaureate Education for Professional Nursing
Practice (2008) and the Essentials for Master’s in Nursing (2011) for nursing education.
The Essentials of Baccalaureate Education for Professional Nursing Practice
(AACN, 2008) addresses genomics in Essential I, V, VII, and IX. These essentials define
the knowledge needed for nursing practice, e.g. basic genetic/genomic concepts,
screening and prevention, genetic diseases and predisposition, pharmacogenomics, family
history and pedigree, and genetic testing and diagnostic trends (2008). Studies have
explored the genomic knowledge of both faculty and undergraduate students (Donnelly et
al., 2017; Munroe & Loerzel, 2016; Read & Ward, 2016). Read and Ward (2016)
compared faculty and student knowledge and found them to be similar. Donnelly et al.
(2017) found that most of the nursing faculty, who participated in their study, lacked
genomic knowledge and confidence in teaching genetic/genomic content. Munroe and
Loerzel (2016) reported that, although students in their study had an increase in genomic
knowledge after a semester of nursing classes, nursing students revealed that they were
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not confident to incorporate genomics into nursing practice. Genomic knowledge and
competencies in baccalaureate nursing education provide a foundation for genomiccompetent nursing practice and serve as the basis for continuing nursing education and
application in nursing practice.
The Master’s Essentials (AACN, 2011) addresses genomics in Essentials I and
VIII and may be applied in Essentials IV, VI, VII and IX. The Master’s Essentials
document describe competencies, that build upon the baccalaureate nursing foundation,
and prepare advanced practice nurses for increased responsibilities in embedding
genomics into direct care activities.

For example advanced practice nurse should

incorporate genetic/genomic evidence in care, translate research and participate in
collaborative teams to improve health outcomes, influence health care policy and finance,
provide patient centered care, and integrate health promotion and prevention in patient
education and nursing interventions. As described in the Master’s Essentials, genomics
can be applied to leadership and quality improvement through mentorship, integration in
organizations, and care delivery to improve patient outcomes. Donnelly et al. (2017)
found that the majority of the doctorally-prepared faculty in their study reported that
Master’s Essentials competencies were not being met in their graduate program.
“As the voice of academic nursing, the American Association of Colleges of
Nursing (AACN) serves as a catalyst for excellence and innovation in nursing education,
research, and practice” (AACN, 2019, p. 3). In 2020, AACN published a DRAFT The
Essentials: Core Competencies for Professional Nursing Education (AACN, 2020). In
this document, domains, competencies and sub-competencies are identified for Entry-
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level Professional Nursing Education and Advanced-level Nursing Education. “In the
new model, competency-based education provides the structure for nursing across degree
programs” (AACN, 2020, p. 16). As the domains, competencies and sub-competencies
are broadly framed, genetics/genomics is referenced only once in Domain 2: PersonCentered Care, Competency 2.2 Communicate effectively with individuals.

In

Advanced-level Nursing Education, sub-competency 2.2j states, “apply personalized
information, including genetic/genomics, to health care (AACN, 2020, p. 24).
The Essentials of Genetic and Genomic Nursing (ANA, 2009) describes
professional responsibilities and outcomes for genetic and genomic competencies and
education, including expectations for recognizing one’s own belief, values, and attitudes;
taking a three generation family history, constructing a pedigree and identifying risk
factors; advocating for services and resources for patients; promoting informed decision
making; recognizing ethical issues with the use of information and technology; and for
understanding relationship of genomics in health promotion and prevention, screening,
diagnosis, and treatment, including pharmacogenomics. Collectively, these publications
have defined and guided genomic nursing education and genomic nursing competencies.
While these documents have been available for over ten years, nurses continue to
report a lack of knowledge and competency in the application of genetics and genomics
in nursing practice (Calzone et al., 2012; Calzone et al., 2013; Coleman et al., 2014;
Daack-Hirsch, Dieter, & Quinn Griffin, 2011; Thompson & Brooks, 2011). Calzone et
al. (2018) led an implementation project in Magnet hospitals using leadership dyads to
increase genomic education and awareness. An important finding from this study was
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that long-term interventions are needed for the successful integration of genomics in
nursing practice (Calzone et al., 2018).
The framework for this dissertation is the Healthcare Genetics (HCG) Model of
Care (Figure 1.1). The model was developed collaboratively by Healthcare Genetic
Ph.D. students and faculty during an HCG course and illustrates the interdisciplinary
nature of genomics. At the center of the model is Healthcare Genetics, which this
investigator expanded to include Genomics.

Linkages extend to the constructs of

genetics/genomics, education, clinical testing and therapeutics, environment, and ethical,
legal, and social implications (ELSI). Green and Guyer (2011) discussed a vision for the
future of genomic medicine which included several of the HCG model constructs, e.g. the
essence of genomics, education and training, and genomics and society, which included
ethical, societal, and policy issues.
Genetics is defined as the study of individual genes (National Cancer Institute,
2020). Genomics is a broader term, defined as the study of all genes and the interaction
among them and the environment (National Human Genome Research Institute, 2020).
Individual genes and their expression influence phenotype at a molecular or cellular level
(Green & Gurry, 2011). A genetic change in deoxyribonucleic acid (DNA) could impact
the transcribed ribonucleic acid (RNA) leading to a translational protein error (Green &
Gurry, 2011).

Understanding the mechanisms by which genes and gene variants

influence health will assist nurses and advanced practice nurses to provide genomic
competent care and education for patients and their families.
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Figure 1.1. Adapted HCG Model of Care.

Genetic and genomic education is important for all healthcare providers,
beginning with their professional education and continuing throughout their careers. A
lack of genomic knowledge and care has been identified in all healthcare providers
(Calzone, et al., 2013; Korf, et al., 2014; Selkirk, et al., 2013). The Institute of Medicine
held a round table discussion in 2016 to discuss barriers to the incorporation of new
genomic technology in clinical practice and identify strategies to increase healthcare
professionals’ genomic education (Dougherty, Wicklund, & Taber, 2016).
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Clinical testing may involve examining genetic changes at multiple levels, e.g.
chromosomal analysis with karyotyping, genetic testing for gene mutations, and protein
analysis. It may also indicate an increased risk for hereditary diseases or conditions and
can be utilized to guide treatment and for pharmacogenetics. With the expansion of
genomic testing as an aspect of clinical testing, the need for nurses to understand the
different types of tests is essential in order to educate and answer questions for patients
and their families (Aiello, 2017).
The environment and modifiable factors such as diet, exercise, and environmental
pollutants can impact an individual’s risk for disease(s) (World Health Organization,
2017). The interaction of one’s environment and their genome can guide the assessment
of individual risk (2017). Nurses’ ability to take an accurate family history and recognize
risks can offer opportunities to educate patients and their families. Also, as members of
the interprofessional healthcare teams, nurses can recognize “red flags” for genetic
testing and participate in interdisciplinary team discussions regarding screenings for
various diseases and conditions.
Ethics plays an important role in the nursing profession and in genomics. The
Human Genome Project (HGP) promoted the establishment of a working group to
anticipate and examine the ethical, legal, and social implications that would arise with
research and discoveries through sequencing the human genome (NHGRI, 2012). This
foresight led to the consideration of potential societal implications of genomic healthcare.
One key policy that arose to offer protections around genomic testing was the Genetic
Information Nondiscrimination Act (GINA).
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Enacted in 2008, GINA was the first

federal policy that prohibited health insurance eligibility and employment discrimination
based on genomic testing results (Steck & Hassen, 2019).
The ANA Code of Ethics (2015) includes genomics and the application of
genomics in nursing practice. ELSI is important for nurses to consider the implications
of genomics in clinical practice and research. For example, genomic testing can be
beneficial in guiding health prevention and promotion recommendations and treatment
discussions. Those benefits must be balanced by potential risks of learning genomic
information that may affect patients and their families in a number of ways.
Although the HCG model shows the relationships between the constructs as bidirectional, all constructs are linked in the model through the Healthcare
Genetics/Genomics core construct. As the application of genomics continues to expand
in healthcare, the HCG model

constructs

can guide the incorporation of

genetics/genomics in nursing program entry level education and continuing education of
nurses and other healthcare professionals to facilitate the use of genomics in patient care
across the healthcare continuum.
In addition to Chapter I, this dissertation comprises four additional chapters that
highlight the application and utilization of genomics in nursing practice.
Chapter II presents an overview of tumor profiling and how genomic testing is
used in the field of oncology. Molecular testing results can be both prognostic and/or
predictive and is used to guide decisions about cancer treatment.

An overview of

genomic tests and their utilization in breast, lung, colon, and prostate cancer is presented.
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The chapter addresses the importance of genomic knowledge and awareness of molecular
testing and biomarkers used to guide personalized medicine.
Chapter III presents an adaptation of Ajzen’s Theory of Planned Behavior (TPB)
model (1991, 2002) and three exemplars applying genomics in nursing practice. The first
exemplar discusses the importance of a complete family health history as a diagnostic
tool to guide decisions about genomic testing and treatment for patients and at-risk family
members. The second exemplar examines the use of genomic testing in cancer and the
impacts on treatment discussions and decisions.

The third exemplar highlights the

influences of financial toxicity, costs and financial impacts on healthcare. Nurses can
provide education, resources, and referrals to mitigate financial stressors to patients and
their families and support other members of the interdisciplinary healthcare team in these
efforts. The chapter closes with a discussion of the importance of having genomiccompetent nurses caring for patients and their families.
Chapter IV presents original research examining the use of genomics in nursing
practice. A mixed-methods study was conducted using Ajzen’s TPB (1991, 2002) as a
framework. The constructs of the model—attitude, subjective norms, and perceived
behavioral control—were examined quantitively and qualitatively related to the use of
genomics in nursing practice (behavior). This chapter concludes with a discussion of the
study findings and recommendations for future research.
Chapter V concludes the dissertation with a summary of the findings in Chapters
II through IV and conclusions drawn from the findings. This chapter also highlights
limitations of the information presented in each chapter.
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Chapter V closes with

recommendations for embedding genomics in nursing education programs, continuing
education, and clinical practice to promote the application of genomic-competent care for
patients and their families.
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CHAPTER II
TUMOR PROFILING

Introduction
Tumor profiling is a molecular analysis to identify alterations in DNA, RNA, and
proteins (Adenoid Cystic Carcinoma Research Foundation, n.d.). Also referred to as
molecular profiling, various techniques are used to analyze the tumor to help guide
treatments and personalized cancer care. As Chu (2011) stated, “In theory, this approach
should result in enhanced clinical efficacy, improved safety profile, and lower overall
pharmacoeconomic costs” (p. 69).

These analyses are already being used in the

diagnostic and treatment guidelines for multiple cancers including breast, lung, and colon
cancers and lymphomas and leukemias. This chapter offers information that will assist
clinical trial nurses (CTNs) working in oncology-specific research with a focus on solid
tumors to understand tumor profiling and how these genetic tests can be interpreted for
application to clinical trials.

Tumor Profiling
Tumor profiling uses molecular analysis to determine characteristics of tumors,
which assists with prognostic assessment, treatment planning decisions, and the
advancement of personalized medicine.

Techniques for profiling include DNA

microarrays, RNA sequencing, and next-generation DNA sequencing. Currently, DNA
microarrays and RNA sequencing are most commonly used in tumor profiling, but as cost
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continues to decrease for next-generation sequencing of DNA, its use will increase
(Walther & Sklar, 2011).
Tumor profiling is being used today to guide treatment plans, such as determining
the use or type of chemotherapy and the use of specific targeted therapies for better
prognosis and outcomes (Chu, 2011; Walther & Sklar, 2011). There has been a shift to
molecular tumor profiling or analysis from testing for single alterations because of the
increasing number of molecular-targeted drugs (Walther & Sklar, 2011). Molecular
analysis allows the tumors to be tested for an array of alterations and mutations, including
base substitutions referred to as single nucleotide polymorphisms, and insertions and
deletions in DNA. These genetic changes in DNA are discussed in Chapter 31 of the
book. These various alterations can activate oncogenes, leading to alterations in the
signal transduction pathways (Walther & Sklar, 2011). The alterations and mutations
identified through tumor profiling can guide treatment decisions to determine an
individual’s likelihood of response to specific targeted therapies (Walther & Sklar, 2011).
When reading information about molecular profiling, one may see the terms
biomarker, single-gene marker, or multigene markers. Biomarker is defined by the
National Cancer Institute (NCI, n.d.-a) as “a biological molecule found in blood, other
body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or
disease. A biomarker may be used to see how well the body responds to a treatment for a
disease or condition.”
Single-gene markers usually refer to a single-gene, protein, or other molecule that
can be used to predict clinical outcomes (Galanina, Bossuyt, & Harris, 2011). These

15

markers include receptors such as the estrogen receptor (ER), progesterone receptor (PR),
or binding sites for key signaling proteins such as the epidermal growth factor receptor
(EGFR) (Chu, 2011; Galanina et al., 2011).
Multigene biomarkers use one analysis to assess multiple genes found in a tumor
(Galanina et al., 2011). Examples of multigene biomarkers assays include Oncotype
DX® and MammaPrint®. A list of currently used tumor markers can be found on the NCI
fact sheet on tumor markers (NCI, 2011).
Biomarkers can be used as prognostic or predictive markers. Prognostic markers
are used to determine the risk or likelihood of the disease recurring (NCI, n.d.-c).
Predictive markers are used to determine if a patient will benefit from a specific
treatment (NCI, n.d.-b). CTNs need to understand the source of the biomarker in the
development of the tumor type and how the test is used (i.e., prognostically or
predictively) to facilitate the correct interpretation.

Kaplan-Meier Survival Curve
Many researchers use Kaplan-Meier estimate curves to illustrate the benefit of a
certain drug or treatment as it relates to patient survival, requiring CTNs to understand
the definition, collect the necessary data for the calculation, and be able to communicate
this information with other personnel working with the clinical trial (Oncology Nursing
Society, 2010). A Kaplan-Meier curve plots the probability of an event occurring at a
specified time; it is also referred to as a product limit estimate (Goel, Khanna, & Kishore,
2010). This estimate is commonly used in clinical trials to illustrate survival time after
treatment. Specifically, it evaluates the number of living individuals who have survived
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after an intervention, such as a chemotherapy drug, over a period of time (Goel et al.,
2010). To calculate this estimate, the total number of subjects living at the start of the
intervention, minus the number of subjects who have died, is divided by the total of
subjects living at the start, at a given point in time (see Figure 2.1 below) (Goel et al.,
2010).
In a Kaplan-Meier survival curve, the x-axis represents time, and the y-axis
represents the estimated probability of survival within a defined population (Vanderbilt
University Department of Biostatistics, 2011). In general, a high start is seen to the left
side of the graph with a decrease as the curve moves to the right of the graph (Vanderbilt
University Department of Biostatistics, 2011). This can be explained by noting that as
time elapses, the number of people decreases; they either died or became lost to followup during the trial. The Kaplan-Meier survival curve is an estimate of survival at a point
in time, not the actual number of survivors at that point in time (Goel et al., 2010).
CTNs may be required to gather survival data for two groups of subjects, such as
in comparison of standard treatment with a new treatment, so that the Kaplan-Meier
curves can be compared. A survival plot would be created for each group, and it would
be important to monitor any gaps between these two curves. A vertical gap indicates that
one intervention, such as treatment, resulted in more subjects surviving at a specific time

Figure 2.1. Survival Probability.
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point compared to the other treatment group (Goel et al., 2010). A horizontal gap
indicates a longer time of survival before one treatment group experienced a certain
fraction of deaths (Goel et al., 2010).

Biomarkers in Specific Cancers
Breast Cancer
Breast cancer researchers use biomarkers to identify subsets of patients (grouping
patients according to positive or negative receptors) with use as both predictive and
prognostic markers. Currently, the presence or absence of ER, PR, and HER2 receptors
is routinely used as a predictive marker to determine patient-specific treatment of breast
cancer (Galanina et al., 2011). Furthermore, multigene biomarkers from the breast tumor
are used as prognostic markers, predicting risk of recurrence. These prognostic markers,
including Oncotype Dx, MammaPrint, Breast Cancer Index, and PAM50 (Galanina et al.,
2011), can help practitioners determine treatment types to use based on the patients’
personal recurrence risk. This approach offers each patient personalized medicine.
The Oncotype DX Breast Cancer Assay is a 21-gene assay that uses reverse
transcription polymerase chain reaction technology on paraffin-embedded tumor tissue to
calculate a recurrence score that correlates with the likelihood of breast cancer recurrence
within 10 years of initial diagnosis (Genomic Health, n.d.-b; Paik et al., 2004). The
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 trial validated the
correlation of the recurrence score as “quantifying the likelihood of distant recurrence in
tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer”
(Paik et al., 2004, p. 2817). Subsequently, in the NSABP B-20 trial, researchers assessed
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the chemotherapy benefit by testing the interaction between chemotherapy treatment and
the recurrence score (Paik et al., 2006). The population used to validate the Oncotype
DX assay was patients with early-stage breast cancer, defined as stage I or II, lymph node
negative, ER positive (Paik et al., 2004).
An Oncotype DX Breast Cancer Assay report contains a recurrence score, a
number between 0 and 100 that correlates to a specific likelihood of breast cancer
recurrence within 10 years of initial diagnosis (Paik et al., 2004). The recurrence score is
calculated from 16 cancer-related genes and five reference genes (reference genes are
those that normalize the expression of cancer-related genes) (Paik et al., 2004; Zhang,
Ding, & Sandford, 2005). The score places patients into one of three categories: low
risk, defined as a score of less than 18; intermediate risk, defined as a score of 18-30; and
high risk, defined as a score of 31 or higher (Paik et al., 2004). Using this score, a
practitioner can determine if a type of treatment will provide a longer disease-free
survival time.

For example, the NSABP B-20 study found that tamoxifen plus

chemotherapy provided a significant benefit in the high-risk group (Paik et al., 2006).
The low- and intermediate-risk groups did not show a significant statistical benefit with
the addition of chemotherapy to the treatment with tamoxifen (Paik et al., 2004).
Ongoing studies are evaluating the intermediate-risk group (Paik et al., 2006). The
National Comprehensive Cancer Network® (NCCN®) and the American Society of
Clinical Oncology guidelines incorporate the use of Oncotype DX for women with ERpositive, node-negative disease and tumors larger than 0.5cm (Harris et al., 2007; NCCN,
2015a).
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Genomic Health implemented further studies, including Eastern Cooperative
Oncology Group 5194, which contributed to the development of a validated 12-gene
algorithm to predict recurrence risk in patients with ductal carcinoma in situ (DCIS)
(Genomic Health, n.d.-a; Solin et al., 2013). This report provides a DCIS score plus two
additional scores: a percentage for any local event recurrence and an invasive local event
recurrence score to be used to guide treatment plans, such as local excision without
radiation (Genomic Health, n.d.-a; Solin et al., 2013).
MammaPrint is another prognostic multigene assay. It targets 70 genes associated
with breast cancer and uses microarray technology to determine a recurrence score for
early-stage breast cancer (van’t Veer et al., 2002). The study focused on women with
early-stage breast cancer, defined as invasive stage I or II (T1 or T2), smaller than 5 cm,
and including both lymph node-positive and lymph node-negative disease (van de Vijver
et al., 2002). MammaPrint stratified the results into two prognostic groups, good or poor,
based on a correlation coefficient predicting recurrence during the first five years after
therapy (van de Vijver et al., 2002). Other studies evaluated the predictive value of
MammaPrint, concluding that chemotherapy plus endocrine therapy had a significant
clinical benefit in the high risk, poor-prognosis groups. The addition of chemotherapy
was not shown to be beneficial to the good-prognosis group (Knauer et al., 2010).
Mammostrat is a third prognostic test for stage I and II, node-negative, ERpositive breast cancer. Mammostrat, is a five-antibody immunohistochemistry panel
targeting expression levels of the tumor proteins SLC7A5, HTF9C, P53, NDRG1, and
CEACAM5 (Bartlett et al., 2010; Clarient Diagnostics Services, GE Healthcare, n.d.).
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An algorithm calculates a risk index score to classify patients into one of three categories
based on the percentage of cancer recurrence in 10 years. The categories include low,
moderate, and high risk for relapse. Women at low risk would probably not receive
additional benefit from chemotherapy, but those at high risk would have long-term
benefit from chemotherapy plus hormonal therapy.

Validation studies have not

incorporated the status of other hormone receptors, but more evidence is supported for
the ER-positive ranking (Bartlett et al., 2010).

Lung Cancer
Strong evidence exists for EGFR, the 5’ endonuclease of the nucleotide excision
repair complex (ERCC1), the KRAS oncogene, and the ALK fusion oncogene as
prognostic and predictive markers (NCCN, 2015b). Additional biomarkers identified for
predictive or prognostic value in non-small cell lung cancer (NSCLC) include the
ribonucleotide reductase enzyme (RRM1) and thymidylate synthase (Andrews, Yeh, Pao,
& Horn, 2011).
EGFR is a transmembrane receptor that is known to have predictive treatment
benefit from EGFR tyrosine kinase inhibitor therapy with the presence of an exon 19
deletion or exon 21 L858R mutation (Miller et al., 2008; Sequist et al., 2008). EGFR
mutation and copy number were positively correlated with a higher response rate and
progression-free survival (Miller et al., 2008). Sequist et al. (2008) showed favorable
clinical outcome for patients with EGFR mutation treated with first-line gefitinib, an
EGFR inhibitor.
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The KRAS oncogene has shown to be prognostic of survival.

Studies have

demonstrated that a KRAS mutation has an unfavorable prognostic value with shorter
survival regardless of treatment (Mitsudomi et al., 1991; Slebos et al., 1990; Tsao et al.,
2007). The ALK gene has been shown in studies to have predictive value of response to
crizotinib, an ALK and MET tyrosine kinase inhibitor (NCCN, 2015b).
Testing for the expression of ERCC1 can provide both prognostic and predictive
information. For prognostic value, a high ERCC1 expression is associated with improved
outcomes in early-stage NSCLC (Olaussen et al., 2006). For predictive value, many
studies have researched its ability to predict response to platinum-based therapies.
Research results have shown that low expression of ERCC1 has improved overall
survival with platinum-based treatment, especially in advanced disease (Andrews et al.,
2011; Olaussen et al., 2006; Simon, Sharma, Cantor, Smith, & Bepler, 2005).
Another identified prognostic factor is the enzyme RRM1. Similar to ERCC1,
studies have revealed that a high expression of RRM1 is associated with an increased
survival in patients with early-stage NSCLC (Zheng et al., 2007). Zheng et al (2007)
divided patients into four subgroups based on the expression of the RRM1 and ERCC1
proteins: high expression of both proteins (high/high), low expression of both proteins
(low/low), high RRM1 expression and low ERCC1 expression, and low RRM1
expression and high ERCC1 expression. The study concluded that high expression of
both RRM1 and ERCC1 had a statistically significant increase in disease-free and overall
survival (Zheng et al., 2007). In addition, several studies focused on the predictive role
of RRM1, wherein patients with a high RRM1 expression are not sensitive to
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gemcitabine-based chemotherapy, and patients with low RRM1 expression have
increased time to survival when the chemotherapy agent cisplatin is added to gemcitabine
(Andrews et al., 2011). Andrews et al (2011) suggested that a screening panel including
more than one biomarker may be more reliable for prognostic purposes based on the
ERCC1 and RRM1 data.

Colon Cancer
Much research is ongoing in the study of biomarkers for additional predictive
values, or further explanations of response to therapy, in people with colon cancer.
Currently, the KRAS oncogene is a biomarker with known predictive value for response
to anti-EGFR monoclonal antibodies (Dienstmann, Vilar, & Tabernero, 2011). A study
by Amado et al. (2008) demonstrated that KRAS mutations have a negative (inverse)
predictive value, meaning that patients with KRAS tumor mutations had better outcomes
after treatment with chemotherapy alone and no monoclonal antibody therapy. However,
in another study, Bokemeyer et al. (2010) concluded that KRAS wild-type (typical gene
without mutation) tumors have increased response rates to chemotherapy with the
addition of a targeted agent. The conclusion from multiple clinical trials, including
retrospective analyses, is that KRAS mutations can be used as a predictive marker for
treatment with anti-EGFR monoclonal antibodies (Dienstmann et al., 2011). Additional
predictive markers for anti-EGFR agents include BRAF, NRAS, and PIK3CA status. The
loss of protein expression by PTEN, a tumor suppressor gene, continues to be
investigated for predicting a lack of benefit to treatment with monoclonal antibodies and
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a negative correlation with overall survival (Er, Chen, Bujanda, & Herreros-Villanueva,
2014).
Similar to breast cancer, colon cancer has genomic profiling options to predict
recurrence risk. These include Oncotype DX, ColoPrint, and ColDx. The Oncotype DX
Colon Cancer Assay (Genomic Health, n.d.-c) is a 12-gene panel consisting of seven (7)
cancer genes and five (5) reference genes (Gray et al., 2011).
Another profiling approach discussed the relationship of tumor gene expression
and risk of cancer recurrence in four individualized cohorts to evaluate surgery alone
versus surgery plus adjuvant 5-fluorouracil (5-FU) plus leucovorin in both stage II and
stage III disease (O’Connell et al., 2010). These researchers used the quantitative reverse
transcription polymerase chain reaction technique to identify 48 genes associated with
recurrence risk and 66 genes associated with benefit of 5-FU/leucovorin (O’Connell et
al., 2010). From this, seven of the recurrence genes and six of the treatment-benefit
genes were identified and are the foundation of the algorithm used to categorize patients
with stage II and III colon cancer into three categories: low, intermediate, and high risk
of recurrence (O’Connell et al., 2010). The development of this assay was validated and
confirmed for stage II colon cancer in the QUASAR (Quick and Simple and Reliable)
and the Cancer and Leukemia Group B 9581 studies. Use of the gene expression levels
of the cancer genes allows for the calculation of a recurrence score. A report is generated
with a colon cancer recurrence score that ranges from 0-100: a score less than 30 has a
recurrence risk of 15% or less; a score of 30 or greater indicates a recurrence risk greater
than 15%; and a recurrence score of 41 or greater indicates a recurrence risk greater than

24

18% that overlaps with T4 patients (Genomic Health, n.d.-c). The report also includes
information on mismatch repair (MMR) status.
MMR is a conserved process during DNA replication that corrects mismatches of
bases (Kunkel & Erie, 2005). A deficiency in MMR identifies a small subset of stage II
colon cancer tumors with significantly lower recurrence risk compared to tumors with
expression (Genomic Health, n.d.-c). A study by Gray et al. (2011) concluded that the
12-gene assay was able to validate the recurrence score for stage II colon cancer tumors
treated with surgery alone but was not validated as a predictive marker for treatment with
adjuvant 5-FU or folinic acid chemotherapy.
ColoPrint (Agendia, n.d.) is an assay that quantifies the expression of 18 genes
and is a prognostic marker that classifies patients into two categories: low versus high
recurrence risk (Salazar et al., 2011). In the development of the ColoPrint assay, 188
tumor samples consisting of stage I, II, and III colon cancers were categorized into A, B,
and C groups based on mutational status of BRAF (Salazar et al., 2011). Then, using the
B group, an 18-gene optimal assay was developed and validated using a sample of 206
subjects. In this study, researchers assessed the mutations for BRAF, KRAS, and P13KCA
in addition to running the 18-gene assay. Based on the ColoPrint analysis, patients were
categorized as having either low or high risk of recurrence based on five-year survival.
The study concluded that ColoPrint improves prognostic accuracy and was able to
identify patients with stage II disease that could be managed without chemotherapy
(Salazar et al., 2011).
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ColDx (Almac Group Ltd., n.d.) is a DNA microarray multigene assay that uses
634 probes to stratify patients as having either high or low risk recurrence (Kennedy et
al., 2011). Kennedy et al. (2011) performed validation on a sample of 144 patients with
stage II colon adenocarcinoma, categorizing them into the two groups based on
recurrence risk at five years. The study also demonstrated that the insulin-like growth
factor, tumor growth factor-beta, and the high mobility group B protein (HMGB1)
signaling pathways were the most significant in the gene signature (Kennedy et al.,
2011); each pathway was reported to promote tumor growth, invasion, and prevention of
apoptosis, or programmed cell death (Nosho et al., 2004, Tsushima et al., 1996, Völp et
al., 2006).

Prostate Cancer
Cooperberg et al. (2013) discussed the use of the Oncotype DX Prostate Cancer
Assay to identify risk of metastasis in men recently diagnosed with early-stage prostate
cancer. The Oncotype DX test reveals the activity of 17 genes and uses an algorithm to
produce an individualized Genomic Prostate Score to indicate the likelihood of tumor
spread to other organs or the bone (Cooperberg et al., 2013). This test is a prognostic
marker that can be used to guide treatment decisions by patients (NCCN, 2015c).

Summary
This chapter summarized some of the biomarkers and gene panels used to predict
treatment and prognosis in different solid cancers. Currently, tests are being developed at
an amazing rate, each with more genes and better predictability. CTNs need to be aware
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of new literature as molecular testing availability increases for each specific tumor type.
Because tumor profiling offers both predictive and prognostic information, CTNs must be
knowledgeable as to which mutations are being used to profile different solid tumors and
if the implications are different in the various tumor types. For CTNs, it enhances an
individualized approach to health care to provide very personalized medicine to patients
enrolled in clinical trials in order to offer new hope for alternative approaches to
diagnosis or new treatment options for their metastatic, resistant, or recurring cancer
(Chu, 2011).
The basics of genetics and molecular analysis on tumor tissue, along with
pharmacogenomics and pharmacokinetics, are discussed in Chapter 31.

Key Points
•

A variety of techniques are used for the molecular analysis of gene and
protein alterations associated with profiling malignancies.

•

Tumor profiling is used to personalize treatment plans to determine the use or
type of chemotherapy or the use of specific targeted therapies for better
prognosis and outcomes.

•

The Kaplan-Meier curve is used in clinical trials to illustrate the benefit of a
drug or treatment as it relates to patient survival.

•

A variety of genes serve as biomarkers for specific cancer types, especially
breast, lung, colon, and prostate, and are used to determine individualized
treatment and prognosis.

•

Genetic testing is being developed that can evaluate the presence of multiple
genes with one assay.

•

Understanding the significance of tumor profiling in oncology clinical trials is
crucial to the role of CTNs in interpreting the correct treatment plan and
educating patients and families.
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Abstract
Genetic and genomic research impacts screening, diagnosis, and treatment of
multiple diseases and conditions. Nurses must be equipped with genomic knowledge,
skills, and resources as a foundation for patient/family education, and to help patients and
families by providing competent, quality genomic patient care.

Ajzen’s Theory of

Planned Behavior (TPB) is useful in applying genomics in nursing practice. This article
presents the TPB and describes how the constructs of attitude, subjective norm, and selfperceived behavior may impact nurses’ intentions and actual behaviors in the delivery of
genomic-competent nursing care. Family history, genomic testing, and financial toxicity
exemplars are presented to illustrate the application of genomic knowledge in nursing
practice.
Keywords:

genetics, genomics, theory of planned behavior, nursing, family

history, genomic testing, financial toxicity.
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Theory of Planned Behavior in Genetic-Genomic Nursing Practice
As genetic and genomic research and technology have expanded, testing is more
readily available, new gene-based treatments are more commonly being used, and
genomic information is increasingly applied in health and healthcare (Calzone, Kirk,
Tonkin, et al., 2018; Stark et al., 2019). Genetics is the study of individual genes, while
genomics is broader and encompasses the study of all genes together, their interactions
with each other and the effects of environmental factors. Common health conditions and
chronic diseases, such as cancer, heart disease, and diabetes are genomic disorders as
they occur due to alterations in multiple genes along with environmental influences
(Feero, Guttmacher, & Collins, 2010). This article will use the broader, more holistic
term genomics to include both genetic (single gene) and genomic (complex) disorders
and interventions.
Genomics plays a role in nearly all diseases and health conditions and
increasingly influences health and care across the care continuum (Calzone, Kirk,
Tonkin, et al., 2018; Leach et al., 2016). As the number and types of genetic and
genomic tests expand, more patients have an option to complete genomic testing. Test
results may guide personalized health promotion and disease prevention activities, or
additional screening and/or treatment. To provide genomic-competent care to patients
and their families, nurses need knowledge of genomic diseases and conditions and their
symptoms and treatments, as well as relevant practice policies and resources. This
knowledge guides the provision of nursing care across the continuum of assessment,
diagnosis, mutual goal setting, planning, implementation, and evaluation.
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Genomic

knowledge and competency are also essential to educate and advocate for patients and
their families (Fu et al., 2019; Williams & Cashion, 2015). Nurses have a professional
duty to develop genomic competency in their initial and continuing professional
education and translate that competency to action in the care and education of patients
and families, and in mentoring colleagues.
Genomic competencies specific to nursing have been articulated and broadly
endorsed by the American Association of Colleges of Nursing [AACN] (2008) and
American Nurses Association [ANA] (2009). However, practicing nurses continue to
report low or poor levels of knowledge and competency in these areas (Aiello, 2017;
Anderson et al., 2015; Calzone, Jenkins, Culp et al., 2013). Nurses require knowledge
about new genomic tests and technologies, and an understanding about which patients
may benefit, as well as evidence-based educational information and resources for patients
and their families. Effective use of genomics in nursing practice requires a behavior
change, which can be challenging. Applying Ajzen’s Theory of Planned Behavior (TPB)
can help nurses to identify challenges and develop strategies to deliver genomiccompetent care. This article provides an overview of Ajzen’s TPB and illustrates the
theory’s application in genomic nursing practice using three practice-based exemplars.

Theory of Planned Behavior (TPB) and Genomic Nursing
Ajzen’s (1991, 2002) TPB is an explanation of the phenomenon of a behavioral
intention or action and is illustrated in Figure 3.1. Ajzen & Fishbein’s initial work (1970,
1980) was described as the Theory of Reasoned Action (TRA) and explored the influence
of attitudes and subjective norms on behavioral intention (the intent of performing an act)

36

Figure 3.1. Theory of Planned Behavior Model Applied to Genomic Nursing.

and the act or behavior occurring. In 1991, Ajzen expanded TRA to the TPB and
included the construct of perceived behavioral control. Perceived behavioral control is
described as an individual’s access to resources and opportunities (non-motivational
factors), which contributes to intention and behavior.
The TPB is comprised of three constructs: attitude, subjective norm, and
perceived behavior control (1991, 2002).

Together, these constructs influence an

individual’s intention to perform some behavior. This theory can be utilized to inform
genomic care in nursing practice (Leach et al., 2016). For example, a nurse may know
how to elicit a three-generation family history and believe it to be an important aspect of
nursing care (attitude), and she/he may work in a setting that supports family history
being embedded into assessment and care (subjective norm). However, if the electronic
health record (EHR) has no option for documenting a complete family history with
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information about the extended family (perceived behavioral control), the nurse may only
document the patient’s personal history and omit information about grandparents, parents
and siblings. Without having a three-generation pedigree readily available, the healthcare
team may not identify genomic risk factors and therefore miss opportunities to implement
recommended screening guidelines or make appropriate referrals. Figure 3.1 illustrates
how each TPB construct influences a nurses’ intention to act in applying genomics to the
care of patients and their families.
Attitude is defined as, “to the degree to which a person has a favorable or
unfavorable evaluation or appraisal of the behavior in question” (Azjen, 1991, p.188).
Attitude can be described as affective or evaluative (Ajzen, 1991; Ajzen, 2002).
Affective attitude is whether the behavior incites positive or negative feelings in an
individual. Evaluative attitude is whether the behavior is viewed as beneficial or harmful
to the individual (Ajzen, 1991; Madden, Ellen, & Ajzen, 1992). A person’s affective
feelings and the perceived benefit of an action can influence both their attitude and their
intention to perform the behavior.
In two studies, almost 70% of nurses felt a need to become more knowledgeable
in genomics, demonstrating a positive affective attitude for genomics.

They also

perceived genomics to be very important to nursing practice (Calzone, Jenkins, Culp et
al., 2013; Calzone et al., 2012). Evidence suggests genomic knowledge can positively
influence evaluative attitude and promote nurses’ use of genomics in practice (Chen et
al., 2018; O’Driscoll et al., 2018; Tanguay et al., 2020). Chen et al. (2018) found that
after nurses and other healthcare providers attended a family health history genomics
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workshop, they exhibited increased knowledge and a more favorable attitude, which led
to an increase use of genomics in their practice as reported in a three-month follow up
survey.
Subjective norm is defined as “. . . perceived social pressure to perform or not to
perform the behavior” (Azjen, 1991, p. 188). Subjective norms reflect attitudes and
behaviors of those who exhibit influence on a person’s behavior. For example, if family
members, peers, or the social network support the behavior and/or perform the behavior
themselves, then an individual is more likely to perform the behavior.
Because nursing care is delivered in teams, nurses work together, mentor each
other, and collaborate to provide the best care for patients and their families. Therefore,
attitudes and behaviors of a nurse on a unit or in a department or institution can influence
the attitudes and behaviors of other nurses. In addition, institutional and unit-specific
nursing competencies, policies, and procedures establish expectations and guide nursing
practice. Embedding genomic-competent nurses with leadership skills influences the
implementation of genomics in practice (Andrews et al., 2014; Leach et al., 2016). In a
multi-site study, genomic training of leadership dyads positively influenced genomic
awareness and intention among nursing colleagues and led to resource development for
integration of genomics in nursing care (Calzone, Jenkins, Culp, et al., 2018).
Perceived behavioral control is defined as, “. . . the perception of the ease or
difficulty of performing the behavior of interest” (Ajzen, 1991, p. 183). Perception
includes both internal and external factors of influence (Godin & Kok, 1996). Internal
factors of influence include a person’s confidence, capability, and ability to overcome
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obstacles and challenges that impact one’s perceived behavioral control. External factors
of influence include cost, access to resources, and transportation (Ajzen, 1991).
In the TPB model, perceived behavioral control also has a direct impact on
behavior/action. For example, in a study of risk reduction in African Americans with a
family history of Type 2 diabetes, researchers examined the influences on behavior
change. While diabetes knowledge and family history awareness were the foci of this
study, the researchers found that perceived individual control over making lifestyle
changes and choices, had the greatest impact on behavior change (Seaborn et al., 2016).
Individually and together, attitudes, subjective norms, and perceived behavioral
control affect a person’s intentions to implement a behavior or take an action, as well as
whether the behavior is actually performed (Ajzen, 2002). Nurses’ limited genomic
knowledge, understanding of the competencies, and lack of confidence can impact their
intention, resulting in the inability to use genomics in nursing practice. TPB can guide
the implementation of genomic-competent nursing care to improve patient outcomes.

TPB Applications in Genomic Nursing
Enhancing nurses’ attitudes, subjective norms, and perceived behavioral control
can increase their behaviors in applying genomics to nursing practice. Three exemplars
are presented to illustrate the impact of nurses’ genomic knowledge and skills on the care
of patients and their families.

The first illustrates how a detailed family history

(pedigree) can alert the need for referral. The second focuses on patient and family
education about genomic testing to guide treatment. The final exemplar describes how
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assessing for and providing needed resources address financial toxicity issues related to
testing and clinical management.

Family History
Nurses at all levels of preparation have a responsibility to assess family history
across the healthcare continuum in every setting and specialty (Calzone et al., 2010).
Genomic nursing competencies outline specific information to gather when eliciting a
family history, including age of disease onset and cause of death (ANA, 2009). Taking a
family history is a non-invasive and economical method to obtain detailed information
that may identify patients at risk for various diseases and conditions (Ford, Rooks, &
Montgomery, 2016; Mahon, 2016).

Exemplar and Discussion: Family History
Mike was diagnosed by his urologist with prostate cancer two years ago at the age
of 60. The nurse in the urology clinic, Susan, collected a focused family history. She
asked Mike about his medical history and any history of prostate cancer in the family.
Unaware of potential genomic implications for Mike and his family, she did not ask
about a history of other cancers in family members. Given a negative family history of
prostate cancer and Mike’s age of 60 at diagnosis, he was not referred for hereditary
(germline) genetic testing.
Now, two years later, Mike’s prostate cancer has been found to have progressed
and a referral to an oncologist is made. At the first visit, the oncology nurse, Linda,
assesses the patient and completes a more detailed family history. Linda asks Mike if
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anyone in his family, including his grandparents, parents, aunts and uncles, siblings, or
children, have any history of cancer, other diseases, or health conditions. This detailed
family history reveals both breast and pancreatic cancer in the pedigree as illustrated in
Figure 3.2. When Linda documents Mike’s family history in the EHR, she also asks
about each family member’s age at the time of their cancer diagnosis, and the age and
cause of death for any family member who is deceased.
Linda discusses the pedigree and family risks with the oncologist. Examination
of the pedigree reveals that Mike’s mother Mary had breast cancer and her brother
George had pancreatic cancer, both of which have been associated with mutations in
BRCA genes. This significant family history is documented in the oncologist’s note and
Mike is referred to a genetic counselor, who recommends germline testing. A deleterious
germline mutation is detected in BRCA2. The identification of the BRCA2 mutation has
several implications for Mike and his family. Based on these results, the oncologist can
offer Mike targeted treatment or a clinical trial for his prostate cancer. In addition, nurses
and/or the genetic counselor can provide education for Mike and his family regarding
testing for the children and implementing recommended guidelines for cancer prevention
and early screening for all family members. In this scenario, Linda’s actions positively
impacted the care management for Mike and his extended family.
A detailed family history is essential to identify all family members who might
benefit from early prevention, screening, and testing to guide clinical management.
Genetic red flags provide guidance in analyzing a pedigree for possible referral to a
genetic counselor or specialist. Red flags include early onset of disease (such as <50
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Figure 3.2. Pedigree Example of Mike’s Family.

years old), multiple affected generations, and ethnic predispositions (Schaa, 2016).
Guidelines for prevention and screening recommendations for patients identified at high
risk have been published by several professional organizations (National Comprehensive
Cancer Network (NCCN), 2019; Mital et al., 2016). Without taking a detailed family
history including age of diagnosis for diseases and conditions, nurses may miss
opportunities to recognize at-risk patients who need referrals. They may fail to educate
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these patients on risk reduction strategies and early screenings and/or make appropriate
recommendations to the multidisciplinary team.
Applying TPB, genomic knowledge can positively influence affective attitudes,
evaluative attitudes and perceived behavioral control, leading nurses to apply genomics in
their practice and improve patient outcomes (Chen et al., 2018; O’Driscoll et al., 2018;
Tanguay et al., 2020).

Nurses need competencies in assessing family history,

constructing a three-generation pedigree (including history of diseases and conditions,
age of onset, with cause and age of death), identifying red flags, and sharing information
with the multi-disciplinary team (American Nurses Association, 2009). Based on this
information, the healthcare provider can discuss options and refer patients for prevention,
screening, and genomic testing if indicated.

By sharing knowledge with patients,

families, and colleagues, genomic-competent nurses will facilitate the integration of
genomic applications in nursing practice.

Genomic Testing
Nurses, depending on their area of practice, should be familiar with different
types of genetic-genomic testing. Genetic testing now extends beyond single gene testing
and often involves multiple genes when testing for either germline or somatic mutations.
Nurses should be knowledgeable about both types of mutations. Germline mutations are
changes in genes that are passed from one generation to another through the DNA in the
gametes and are present in the DNA of every cell (NCI, 2020).

When germline

mutations are suspected, a referral to a genetic counselor is indicated for in-depth testing.
Somatic mutations are mutations that occur in specific cells after conception and are not
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inherited or passed down to children (NCI, 2020). A variety of tests are available to
identify somatic mutations, particularly in cancer cells. Next-generation sequencing
(NGS) is technology that allows DNA sequencing of the genomes of particular tissues
(Yohe & Thyagarajan, 2017), e.g., sequencing tumor DNA or sequencing fragments of
tumor DNA that are found in blood (a liquid biopsy) (Alix-Panabieres, 2020).
Beginning in the 1980s, a type of genetic testing known as companion diagnostic
testing was introduced to determine whether a therapeutic treatment is likely to benefit a
patient, based on the patient’s genomic profile. The test and the linked therapy are
“companions” (Agarwal, Ressler, & Snyder, 2015; Stockley et al., 2016). Examples of
companion diagnostics include testing for mutations in genes such as EGFR in non-small
cell lung cancer, BRAF in melanoma, and KRAS in colon cancer. When a patient with
non-small cell lung cancer is tested and a particular mutation, e.g., EGFR L858R, is
found, identification of the mutation guides the oncologist to select a treatment targeted
to that mutation, such as erlotinib (Tarceva®), osimertinib (Tagrisso®), or gefitinib
(Iressa®). Nurses’ knowledge of genomic testing and treatments allows them to answer
questions and provide resources for patients and families.

Exemplar and Discussion: Genomic Testing
Karen, a 58-year-old woman, had a screening colonoscopy during which a polyp
was discovered, removed, and sent to pathology for testing.

The pathology report

revealed she had colon cancer. Karen was scheduled for a colon resection to remove the
area of identified cancer and surrounding lymph nodes. When Karen followed up with
her surgeon, Dr. Cook, she learned the pathology showed local invasion of cancer cells
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through the mucosa and two positive lymph nodes. Dr. Cook told Karen she had stage III
colon cancer and referred her to an oncologist to discuss further treatment with
chemotherapy. To determine the best treatment regimen, Karen’s oncologist explained
that her tumor tissue was being tested for a harmful mutation within the KRAS gene in a
companion diagnostic test. If a KRAS mutation was identified in the tumor cells, standard
chemotherapy would be started; if no mutation was found, a monoclonal antibody would
be added to the chemotherapy treatment regimen (NCCN, 2020b).
As no KRAS mutation was identified, Karen began a standard of care treatment
regimen, FOLFOX (leucovorin calcium, fluroucaril, and oxaliplatin) with the addition of
a monoclonal antibody. Now, six months after Karen completed the initial treatment
regimen, a follow-up CT scan is ordered which reveals evidence of a lesion in the liver.
A biopsy is performed, and the pathology report indicates Karen now has stage IV
metastatic colon cancer. Her oncologist orders next-generation sequencing of the liver
lesion tissue to identify mutations specific to her cancer metastases, as these findings can
guide treatment decisions and indicate appropriate clinical trials based on mutations
found. Karen’s NGS results show mutations in the ATM, TP53, and PALB2 genes in her
metastatic tumor cells. Accordingly, the oncologist proceeds with second line standard of
care treatment per clinical guidelines. Information in the genomic report can also be used
to guide future discussion about options for off-label treatments and clinical trial options.
The KRAS companion diagnostic test is a somatic single-gene test performed on
tumor tissue to identify a mutation in a specific single gene (KRAS), to guide selection of
treatment options.

NGS is a somatic multi-gene DNA analysis which provides
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information about many genes and is often completed in the presence of metastatic
disease or when cancer progresses despite treatment.

By identifying mutations in

primary or metastatic tumor tissue, NGS allows selection of therapeutic treatments
targeted to particular gene mutations and may lead to identification of clinical trials
available for patients with a particular mutation profile.
The use of companion diagnostic testing guides personalized cancer treatment and
leads to better outcomes and longer survival (Stockley et al., 2016). In recent years,
genome science has identified a number of proteins, hormone receptors, and other
biomarkers that are associated with carcinogenesis and indicate which therapies are most
likely to be effective.

Karen’s case provides an example in which a companion

diagnostic test for a KRAS mutation indicate whether a particular treatment (in this case
monoclonal antibody therapy) should be added to a patient’s chemotherapy regimen.
Another example is testing for the HER2 protein in breast cancer. If the HER2 protein is
overexpressed on the surface of tumor cells, then a targeted therapy such as trastuzumab
(Herceptin®) is included in the treatment regimen. This approach has shown drastic
reduction in the size of tumors (NCCN, 2020a). The KRAS mutation and HER2 protein
are examples of identifiable targets that allow targeted therapies to be included in a
patient’s treatment regimen which can improve their response to treatment and survival.
Using TPB, as illustrated in the exemplar, genomic testing knowledge and
resources influence attitudes, subjective norms, and perceived behavioral control.
Knowledge of genomic testing and its use guides treatment discussions and decisions. As
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part of the interdisciplinary treatment team, nurses answer patient and family questions;
educate them about treatment options; and provide support during and after treatment.

Financial Toxicity
Financial Toxicity is defined as patient concern related to the cost of medical care
(NCI, 2020). Financial toxicity affects both non-insured and insured patients. Concerns
about health costs for non-insured patients can deter persons from seeking health care. In
addition, treatment costs can lead to debt and bankruptcy. Even patients with health care
insurance may experience burdensome health costs from high premiums, deductibles,
copayments, and non-covered treatments. Financial toxicity is especially likely to affect
patients being treated for cancer, which is among the costliest health conditions in the
United States, with many treatments costing more than $10,000 per month (NCI, 2020).
Genomic advances such as companion diagnostics and multi-gene testing can lead
to targeted therapies that are effective; however, both testing and the treatments are very
expensive, even for people with insurance coverage. Recent research identifies that the
high cost of quality cancer care limits access to recommended management and is
associated with reduced therapy compliance, diminished quality of life, and increased
mortality (Carrera, Kantarjian, & Blinder, 2018; De Souza et al., 2017; Yousuf Zafar,
2016). To provide holistic care that recognizes multiple determinants of health, nurses
need to incorporate patients’ social factors and knowledge of available health services in
order to identify available resources (Office of Disease Prevention and Health Promotion,
2020).
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Exemplar and Discussion: Financial Toxicity
Sue, who has been living with breast cancer for 8 years, recently learned that the
cancer has spread to her liver despite her current treatment. At Sue’s initial diagnosis,
breast biomarker testing was performed on the original biopsy tissue. Breast biomarkers,
estrogen receptor (ER), progesterone receptor (PR), and HER2 protein expression are
routinely completed at initial diagnosis to guide decisions about clinical treatment, which
may include surgery, chemotherapy, and/or radiation.

Now that Sue has stage IV

metastatic cancer, the oncologist orders somatic multi-gene sequencing (NGS) of
metastatic tumor tissue from a recent liver biopsy to identify any additional treatment
options or clinical trials for which Sue would be eligible.
NGS is usually performed when a patient is diagnosed with metastatic, stage IV
cancer or with progression to stage IV disease despite treatment. Testing of metastases is
useful due to cancer’s genomic instability. Genomic instability refers to acceleration of
the rate of errors that occur as cancer cells divide, resulting in new mutations that
accumulate in subsequent generations of cancer cells (Tubbs & Nussenzweig, 2017).
Metastatic cells therefore have additional mutations that were not present in cells of the
primary tumor. Genomic instability occurs due to the loss of DNA repair mechanisms
that protect normal cells (Tubbs & Nussenzweig, 2017). Most NGS is ordered with
disease progression since there is an increased chance to find a mutation due to the
genomic instability and cancer progression.
Sue returns to clinic today for a follow-up visit to receive her NGS results.
Sequencing shows a PIK3CA mutation in the metastatic cells. Alpelisib (PIQRAY®) has
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been approved by the Federal Drug Administration (FDA) for PIK3CA mutated, hormone
positive (ER and PR), HER2 protein negative breast cancer. Based on Sue’s known ER
and PR positive, HER2 negative biomarkers from her earlier testing, along with the
identification of the PIK3CA mutation in metastatic cells, the oncologist will discuss
treatment with PIQRAY, which costs an estimated $19,000 per treatment each month.
Patients typically remain on this treatment until their cancer progresses or side effects
make treatment intolerable. Although PIQRAY and other targeted therapies are FDA
approved, many have high co-payments.
When Sue is seen for her follow-up appointment, the nurse, John, asks her about
any symptoms she is experiencing. Sue tells John that she has had increasing pain and
fatigue, but no nausea, vomiting, or diarrhea. When John asks Sue how her pain and
fatigue are impacting her activities of daily living, Sue begins to cry and says that she has
not been able to work for 3 weeks. The loss of her income has significantly impacted her
family and she is concerned about losing her job and what it could mean for her family,
income, and insurance coverage.
After Sue and the oncologist discuss the recommended treatment with PIQRAY,
John seeks approval for the targeted therapy from Sue’s insurance company and copayment assistance from the pharmacy.

He involves the multi-disciplinary team,

including a nurse navigator and social worker, to support Karen. John’s recognition of
the multiple determinants of health, including costs and the impacts of side effects of
cancer and cancer treatment on daily activities for patients and their families, prompts
him to assess Sue’s resource needs; identify and provide information about available
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resources; and make appropriate referrals. These nursing behaviors are part of providing
holistic care and are associated with improved patient outcomes.
Financial toxicity impacts medication adherence, health outcomes, and quality of
life (Neugut et al., 2011; Dusetzina et al., 2014; Yousuf Zafar, 2016). Transportation
needs, medication costs, genomic testing costs, and unnecessary follow-up visits can
impact costs of care. Lack of resources have been noted as a barrier to care in multiple
studies (Curtis et al., 2019; Sperber et al., 2016). Having financial aid forms, medication
assistance programs, and resources available for patients who are undergoing genomic
testing and treatment helps nurses to address and ease patients’ financial concerns.
Involving nurse navigators, social workers, and the entire healthcare team in assessing
needs, coordinating care, and providing care offers support to patients and their families
during treatment into survivorship.

Utilization of nurse navigators and a

multidisciplinary healthcare team approach can offer opportunities for open discussions
about stressors experienced by patients and their families, leading to support, improved
care coordination, and resource utilization (Fessele, 2017).

The Oncology Nursing

Society (2017) offers a variety of resources for nurses, including an Oncology Nurse
Navigator Toolkit with a module on, “Helping Patients Navigate Financial Issues”.
The TPB constructs of attitude, subjective norms, and perceived behavioral
control have direct influence on behaviors nurses perform. Nurses’ awareness of the
benefits of reducing stress (positive attitudes) for patients and their families by providing
resources, with a supportive multi-disciplinary team that collaborates to provide holistic
care, can increase nurses’ intention and use of genomics (behavior). Connecting patients
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and their families with nurse navigators, social workers, financial assistance programs,
and other resources are important aspects of applying genomics in nursing practice.

Conclusions
The utilization of genomics in healthcare has increased exponentially in the postgenome era. Research has demonstrated the positive impact of genomic applications in
health promotion, prevention, screening, testing, detection, and treatment of various
diseases and conditions. Nurses have a responsibility to educate themselves and their
patients about genomics and apply their knowledge and skills in their care of patients and
families.
Ajzen’s TPB guides understanding of how intentions and behaviors are influenced
by attitudes (affective and evaluative), subjective norms, and perceived behavioral
control. The exemplars demonstrated the impact of the TPB constructs on the application
of genomics (behavior). Understanding the influences of these constructs on nurses’
intentions and actual behavior can inform strategies to promote genomic-competent care.
As members of the healthcare team, nurses make critical contributions to patient
outcomes by completing patient risk assessments; providing support; facilitating referrals,
testing and resources; and participating in discussions about evidence-based treatment
decisions. The advancement of genomics in nursing requires nursing knowledge and
awareness of recommended guidelines, cultivation of genomic nursing leaders,
institutional support, and evidence-based resources for patients and their families. In this
way, nurses at all levels will be empowered to incorporate genomics into their nursing
practice.
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CHAPTER IV
ASSESSMENT OF GENOMIC USE IN CLINICAL NURSING PRACTICE
Abstract
Aim:

To describe nurses’ attitudes, perceptions, and experiences with the

application of genomics in nursing practice and what barriers are identified to its use.
Background:

Genomics impacts patient and families across the health care

continuum. Research reveals a gap between genomics in nursing education and practice.
While nursing students, faculty, and nurses’ genomic knowledge and confidence are
consistently reported as ‘low’, less is known about how genomics is used by nurses in
hospitals.
Design: Cross-sectional study.
Methods: A mixed-methods study was conducted with registered nurses at two
hospitals. A 28-question survey, based on the Theory of Planned Behavior (TPB), was
distributed electronically to nurses at two hospitals (n=151, quantitative component).
The survey results were used to develop focus group questions for an in-depth
exploration of barriers to applying genomics in nursing practice (n=7, qualitative
component).
Results: The survey revealed that most participants lacked genomic knowledge
and felt unprepared to take a family history with a genetic focus, identify “red flags” for
inherited disorders, and use genomics with genetic testing, medications, patient teaching,
and referrals. Six themes emerging from focus group discussions on the application of
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genomics in nursing practice were:

knowledge, family history, genetic counseling,

genomic testing, support and barriers.
Conclusions: Nurses need genomic knowledge and resources to answer patient
and family questions, provide patient education, and deliver genomic-competent care.
Based on these findings, implementation research using the TPB is needed for nurses to
promote the use of genomic-competent care.
Relevance to Clinical Practice:

Nurses need genomic knowledge gained

through nursing entry level and continuing education program, and institutional support
for the application of genomics in nursing practice.
Keywords: genomics, nursing practice, Theory of Planned Behavior

Introduction
Genomics impacts screening recommendations, diagnosis, and treatment of
patients, requiring nurses to have an increased knowledge in genomics for patient care
(Calzone et al., 2012). Research findings reveal a gap between genomic knowledge and
the application of genomics in nursing practice (Aiello, 2017, Anderson et al., 2015,
Calzone, et al., 2013; Calzone et al., 2012). The American Nurses Association ([ANA],
2009) published the Essentials of Genetic and Genomic Nursing: Nursing Competencies,
Curricula Guidelines, and Outcome Indicators.

These competencies guide nursing

faculty in developing curricula that embed critical genomic concepts to prepare nurses for
genomic-competent care.

Although the Essentials were first published in 2006,

investigations reveal a gap between nursing education and genomic literacy (DaackHirsch, Dieter, & Griffin, 2011; Kirk et al., 2011; Calzone et al., 2013; Read & Ward,
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2016).

Ajzen’s Theory of Planned Behavior (TPB, 1991, 2002) was used as the

framework for this study. The purpose of this mixed methods study was to explore the
attitudes, subjective norms, and perceived behavioral control that impact nurses’
intentions and use of genomics in nursing practice.

Background
Daack-Hirsch et al. (2011) assessed the genetic literacy of faculty and students
and concluded that faculty needed to be aware of their own knowledge in order to prepare
nursing students with genetic knowledge. In their benchmark survey of 1000 nurses,
Calzone et al. (2013) found that only 15% had a genomics course in their nursing
education program. Kirk et al. (2011) examined nursing curricula and identified five
barriers to the integration of genomics, including educators’ lack of knowledge, lack of
awareness at the government level, limitations of resources, lack of the ‘patient voice’,
and lack of evidence regarding outcomes.
The Secretary’s Advisory Committee on Genetics, Health, and Society
([SACGHS], 2011) examined education and training issues for point-of-care health
professions, including nurses, public health providers, and consumers and patients. The
commission found a lack of genetic literacy in faculty, a limited incorporation of genetics
in already “crowded” curricula, and the presentation of genetics content that did not lead
to long-term knowledge retention were barriers to translating new genetic knowledge into
practice (US Department of Health and Human Services [USDHHS], 2011). Read and
Ward (2016) surveyed nursing faculty about genetic/genomic knowledge and compared
these results to a previous survey of students. Most faculty respondents rated their
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genomic knowledge as “fair” or “poor,” which was consistent with their mean score of
48% on the Genomic Nursing Concept Inventory (GNCI), a scale used to measure the
understanding of genetic/genomic concepts most critical to nursing practice (Ward et al.,
2014).

Faculty performance on the GNCI was slightly higher than students, who

achieved a mean score of 42% correct. Read and Ward (2016) recommended that faculty
need to be proactive in seeking out genomic education as student competency is
dependent on faculty knowledge, understanding, and competency in genomics.
In addition, SACGHS also noted that genomic competencies were not reflected in
the standards for licensure (USDHHS, 2011). The National Council of State Boards of
Nursing (NCSBN) is the regulatory body for the licensure examination which all nursing
program graduates are required to pass in order to be licensed and practice as registered
nurses. The current test plan has the term genetics/genomics listed only once and it is in
relation to health history and risk assessment (NCSBN, 2018). The lack of substantive
inclusion of genomics in the National Council Licensure Examination (NCLEX) test plan
illustrates the gap between genomic nursing education and practice.
A lack of genomic knowledge has also been found in practicing nurses. Calzone
et al. (2013) found that over half of the 619 nurses in their study reported their knowledge
of genomics as “poor” to “fair” and had never heard of the ANA Essentials (2009).
When examining the of integration of genomics in practice, they also found that 60% of
the participants lacked family history assessment skills.

A baccalaureate nursing

education was correlated with the likelihood of “often” or “always” collecting a family
history (Calzone et al., 2013). In a study of nurses, Rogers et al. (2017) measured
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genomic knowledge after a 12-month education initiative at a Magnet hospital. Their
results revealed that repeated education and exposure was needed to prepare nurses for
the application of genomics in practice.

Calzone et al. (2013) recommend that an

immediate challenge for nursing is to prepare a genomically competent workforce.
Rogers et al. (2017) reiterated the importance of genomic as nurses have an essential role
in providing genomic-competent care.
While studies provide guidance on genomic application in nursing, including the
use of case studies, research on the use of genomics in nursing practice from the nurses’
perspective is lacking.

This study was guided by two research questions.

The

quantitative question is: What are the attitudes, perceptions and experiences of registered
nurses at two upstate South Carolina hospitals regarding the application of genomics in
their practice? The qualitative question is: What are the attitudes, perceptions and
experiences of registered nurses at two Upstate South Carolina hospitals regarding the
barriers to application of genomics in their practice?

Methods
Setting
The study was conducted at two upstate South Carolina hospitals, one with 461beds and the other 540-beds.

Clemson University and each hospital’s Institutional

Review Board (IRB) approved all procedures.
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Design
A mixed methods design was used for this descriptive study. Quantitative data
was collected using a Qualtrics® survey questionnaire. Qualitative data was obtained
through focus group interviews.

Theoretical Framework
Ajzen’s (1991) Theory of Planned Behavior (TPB) was used as the framework for
this study.

TPB constructs are attitude, subjective norm, and perceived behavioral

control, all of which influence behavioral intention. Attitude is defined as, “to the degree
to which a person has a favorable or unfavorable evaluation or appraisal of the behavior
in question” (1991, p. 188). Subjective norm is defined as “. . . perceived social pressure
to perform or not to perform the behavior” (1991, p. 188). Perceived behavioral control
is defined as, “. . . the perception of the ease or difficulty of performing the behavior of
interest” (1991, p. 183). Individually and collectively, attitudes, subjective norms, and
perceived behavioral control affect a person’s intentions to implement a behavior or take
an action, as well as whether the behavior is performed (Ajzen, 2002). Leach et al.
discussed theories associated with the implementation of genomics in nursing practice
and identified Ajzen’s Theory of Planned Behavior (TPB) as the “core underpinning
theory” (2016, p. 311). TPB constructs can be used to understand the application of
genomics in nursing practice, identify barriers in its use, and make recommendations
about strategies to promote the application of genomics in nursing practice.
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Quantitative Methods
The quantitative research question is: What are the attitudes, perceptions and
experiences of registered nurses at two upstate South Carolina hospitals regarding the
application of genomics in their practice?

Sample
A convenience sample of registered nurses (RNs), who provide direct care to
patients were invited to participate in the study through an email invitation, by hospital
administration, with a link to the consent form and survey. Inclusion criteria were
associate or baccalaureate degree in nursing, not currently enrolled in school, working in
a clinical setting, licensed as a registered nurse in South Carolina, and not a travel nurse.

Instrumentation
Respondents were required to select ‘I consent’ to continue to a 27-question
Qualtrics survey. The survey was designed by the investigator, based on the constructs of
TPB, to investigate the application of genomics in nursing practice. The first seven
questions elicited demographic information about the respondents, including nursing
experience and genomic nursing education. Using Ajzen’s (2002) TPB questionnaire
development considerations, 15 questions were developed which described nurse’s
attitudes regarding genomics; their experience using specific genomic concepts based on
established genomic competencies; and nursing administration and colleague support of
genomics at the healthcare institution or on the nursing unit.

Responses to these

questions were measured using Likert scales with counterbalanced adjective pairs as
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endpoints (positive and negative).

Four questions asked about the use of specific

genomic competencies in nursing practice (Yes or No responses).

The final two

questions allowed open-ended narrative responses to explore respondents’ views on the
barriers and challenges which impacted the use of genomics in their nursing practice and
about their experience with genomics.

The survey questions were independently

reviewed by genetic and research members of the investigator’s Ph.D. dissertation
committee to validate that questions addressed the TPB constructs.

Analysis
Descriptive statistics, including means, modes and percentages, were calculated
for the responses on the 28-item survey. Results were analyzed individually for each
item and collectively for each TPB construct.

Qualitative Methods
Research Question:

What are the attitudes, perceptions and experiences of

registered nurses at two upstate South Carolina hospitals regarding the barriers to
application of genomics in their practice?

Sample
A convenience sample of nurses who participated in the quantitative survey were
recruited for a focus group held at each of the Upstate South Carolina hospitals.
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Procedures
Nurses, who responded to the quantitative survey, were invited to participate in
the focus group by emailing the investigator after competition of the survey. A one-hour
focus group was held at each Upstate of South Carolina hospital to conduct an in-depth
exploration of the application of genomics in nursing practice. Participants received and
signed a consent form prior to the start of each focus group. Participants were informed
about the study purpose and that the session was being recorded with a digital audio
recorder and a video camera as a backup (sound only). Prior to the start of each focus
group, a brief statement about the research and a definition of genomics was read. At
each focus group, refreshments were available, and each participant’s name was placed in
a drawing for a year’s membership in a nursing organization of the participant’s
choosing, held at the end of each focus group session.
In each focus group, the investigator and focus group moderator read the same 10
open-ended questions. These questions were developed by the investigator based on the
quantitative survey results (TPB attitudes, subjective norms, and perceived behavioral
control) and on the nurses’ intention to apply genomics in nursing practice. For example,
over 50% of nurses reported “little” to “no” comfort in taking a family history on the
survey. This information guided the development of the following focus group question,
“Describe how you take a family history on your patient? Which family members do you
include in the history?” Family history, attitude towards genomics, genomic education,
genomic tools in the electronic health record, and barriers to use were explored in each
focus group. After each session, responses were transcribed verbatim by the investigator.
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The identification of emergent themes and patterns of meaning were completed using
content analysis and using NVivo, a qualitative data analysis software.

Analysis
The investigator read through each transcript twice to familiarize herself with the
data prior to coding. During the third reading, the investigator highlighted repeated terms
in each transcript and made a list of the terms which were used to identify emergent
themes. Next, the transcribed files were uploaded into NVivo for analysis. Nodes were
entered to code the transcribed data, and emergent themes and patterns were identified.
The transcripts, data, emergent themes and patterns of meaning were reviewed for rigor
and accuracy by a qualitative methodologist, who did not have a background in genomics
or nursing.

Findings
Quantitative Findings
Participant Demographics
One hundred and fifty-one registered nurses, employed at two upstate South
Carolina hospitals, completed the survey. The typical respondent was female (93%),
white (93%) and held a baccalaureate degree in nursing (77%). Nurses who participated
in the study were more likely to have a baccalaureate degree than other nurses in South
Carolina ([50%], (South Carolina Office for Healthcare Workforce, 2018) or nationally
([41.7%], NBSBN, 2017). National data is based on RNs who reported a BSN as the
degree that qualified them for their first US nursing license. Thirty-four percent of the
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respondents reported they had learned about genomics in nursing school, but only 8% had
a genetics/genomics course in their nursing program.

The participant’s nursing

experience ranged from 1 to 56 years (mean=14 years, mode=5 years).

Table 4.1

presents the nursing specialties in which study participants were working.

Survey Results
The survey examined TPB’s constructs (attitude, subjective norms, and perceived
control behavior) applied to genomics using 5-point Likert scales.
measured by two questions.

Attitude was

For affective attitude (if the use of genomics elicited

positive or negative feelings) 43% of the respondents rated their attitude as a 4 or 5
(positive) and 50% reported neutral attitude (3). When asked about evaluative attitude (if
the behavior is beneficial or harmful to the individual), 44% responded that genomic
information was beneficial for patients, 19% responded that it was overwhelming, and
37% had no opinion.
Subjective norms (a reflection of those who influence nurse’s attitudes and
behavior) was measured by questions on the institution, nursing management, and peers.
Most participants reported “little” to “no” support for using genomics by the nurse
manager or leader and the institution as shown in Table 4.2. The majority (92.67%) rated
their peers as using genomics “little” or “none at all.” Genomic concepts were not
included in unit competencies for the majority (91%) of these nurses.
To investigate perceived behavior control (the perception of how easy or difficult
it is to perform the behavior), questions were asked about experience with genomic
concepts based on the competencies endorsed by the American Association of Colleges
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Table 4.1. Specialty Type.
Nursing Specialty
Medical-Surgical
Oncology
OB
Pediatrics
Cardiac
Other
Total

# of Nurses
30
9
12
6
34
58
151

% of Nurses
21.19%
5.96%
7.95%
3.97%
22.52%
38.41%
100.0%

Table 4.2. Subjective Norm Responses.

Questions:
Does your manager/ leadership
support the use of genomics in
your practice?
Does your clinical organization
demonstrate support towards
genomics?
Do your peers utilize genomic
practices or competencies in their
clinical practice?
Does your hospital or unit
competencies include genomic
concepts?

A Great
Deal
2.67%

A Lot
6.67%

Moderate
Amount
20%

26%

A Little
26.67%

None
at all
44%

27.33%

37.33%

1.33%

8%

1.32%

0%

5.96%

32.45%

60.26%

0.67%

0.67%

7.33%

14.67%

76.67%

of Nursing ([AACN], 2008) and American Nurses Association ([ANA], 2009). These
included: family history, identification of ‘red flags’, pharmacogenomics, and genetic
testing. As presented in Table 4.3, these nurses reported “little” to “none at all” comfort
or experience applying genomic concepts in nursing practice, e.g., obtaining a family
history 54%, identifying “red flags” 63%, using genetics for appropriately identifying
medications for patients (pharmacogenomics) (91%), knowledge and experience with
genetic testing (96%) and identifying referrals (94%). Survey revealed that 77.48%
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Table 4.3. Responses on Experience with Genomic Concepts.

Questions:
How would you rate your comfort
level with obtaining a family history
of a disease/disorder?
Do you have any experience with
identifying ‘red flags’ of inherited
family diseases/disorders?
Do you have any experience using
genetics for appropriately
identifying medications for your
patient (pharmacogenomics)?
I have ___ knowledge and
experience with genetic testing in
the clinical setting?
I have _____ experience identifying
when patient should be referred for
genetic testing?

A Great
Deal
9.27%

A Lot
14.57%

Moderate
Amount A Little
22.52%
27.81%

None
at all
25.83%

0.0%

9.27%

27.81%

41.72%

21.19%

0.0%

2.65%

5.96%

19.21%

72.19%

0.0%

1.32%

2.65%

33.11%

62.91%

0.66%

1.32%

4.64%

37.09%

56.59%

of nurses do not take a three-generation family history as recommended by the ANA
Essentials of Genetic and Genomic Nursing (2009).
The final asked participants whether they used genomics in nursing practice and if
they utilized resources (behavior). The overwhelming majority (80%) responded they did
not currently use genomic concepts or services (genetic counselors or testing) in their
nursing practice. Of the 12% who used genomics, the use was related to genetic testing,
referrals for genetic counseling, oncology research, anesthesia, breast cancer, Type 2
diabetes, and cardiac care.

Only 12% of those surveyed utilized genomic tools or

resources either on their unit or online, e.g., breast cancer gene testing, research studies,
and National Comprehensive Cancer Network (NCCN) Guidelines. Documentation tools
used included the following: family history (EPIC®), admission history, and referral for
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other genetic testing. Of these participants, 21% had spoken to a healthcare provider
about a high-risk patient regarding genetics.
The quantitative survey concluded with two open-ended questions: one which
asked barriers and challenges these nurses experienced utilizing genomics in practice, and
the other perceptions or experiences with genomics. The most common responses to
barriers and challenges were little knowledge/lack of education about genomics (39%),
not seeing genomics as applicable to their practice (19%), not enough time/time
consuming (11%), and cost of testing (6%). Other perceptions nurses shared about
genomics included a desire to learn more about genomics and available resources. The
nurses described additional genomic experiences such as having personal genetic testing,
working with genetic counselors in oncology, and seeing the impact of genomics on
cancer patient treatment.

Qualitative Findings
Participant Demographics
Sixteen nurses responded to the invitation to participate in the focus groups. Due
to challenges in scheduling a time for the focus groups related to the participants working
different shifts, only seven nurses (Hospital 1=4, Hospital 2=3) participated in a focus
group. Five nurses worked on inpatient units (oncology, labor and delivery, neurology,
and recovery) and two nurses worked in a hospital-based outpatient clinic (oncology
support).
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Themes
Six themes emerged related to participants’ use of genomics in nursing practice:
knowledge, family history, genetic counseling, genomic testing, support and barriers.

Knowledge
Knowledge was a broad theme that included three sub-themes, “understanding,”
“educate,” and “competency.” The following quotations of participants captured feelings
about the value of genomic knowledge, “You want to speak with confidence and that’s
something that’s hard to speak confidently about because…it requires such a knowledge
base” and “. . . involving those people who specialize. . . in that knowledge field
[genomics] is imperative.” The participants discussed their lack of genomic knowledge
and education which they believed impacted their use of genomics in practice and their
ability to educate patients and families.
Participants were interested in additional genomics education. The importance of
genomics was discussed, by the focus group, related to increasing their knowledge for
their own understanding and so that they would be better prepared to educate patients.
One participant stated, “Understand your subject better [and] you’re able to educate
people.” Participants also discussed their desire to have training on genomic topics and
about referral resources for testing. One participant shared that when she looked for
genomic educational opportunities, she did not see any announcements or notifications
for genomic continuing education. Another participant shared that she had started the
Oncology Nursing Society (ONS) genomics course because it was available at no cost.
However, she was unable to finish the course due to the amount of information presented
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during the time-period that access was allowed. Finally, there was lack of awareness
about the genomic competencies published by the ANA (2009) and AACN (2008, 2011).

Family History
To explore family history, participants were asked if they took family histories,
how many generations they inquired about, and how they documented family histories.
The responses ranged from taking at least a two-generation pedigree, including age and
cause of death of those deceased, to only asking about a patient’s history.

An

experienced, acute care participant shared, “So back then, we would kind of ask about
family history but now we don’t really. We ask about a patient’s history, but family
history is done in the offices and is put in there. If anesthesia sees the patient, they will
ask a little bit more in depth family history.” An oncology nurse participant stated, “I
usually think about two generations and ages at diagnosis and which specific diagnosis
[the person] had or passed away from.” One participant related the lack of depth in
asking about the family history to the electronic health record, “Our EPIC. . . I’m not sure
it goes that deep into family history.”

Genetic Counseling
Asking participants about their experiences with genetic referrals, they discussed
genetic counseling. One participant stated that the time slots for genetic counseling were
filled at their institution, thus illustrating the need. Another participant shared that she
called patients to explain the purpose of genetic counseling and testing. This participant
stated, “Any of the physicians can refer for genetic counseling. I can only speak to that.
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But our priority is given to patients that need the appointment for a treatment decision.”
The participants in the focus groups shared that genetic counselors were involved in the
oncology multidisciplinary conferences at both hospitals.
Participants felt that genetic counselors should be involved when the patient is
undergoing genetic testing because these counselors understand the ethical issues and
treatment implications. One participant stated, “Involvement of the genetic counselor
involves more than just delivering a test result.” Another expanded on this by saying, “. .
. [when] consenting someone for a test… they [genetic counselors] involve things like
ethics and . . . the implications of knowing or not knowing [the genetic testing results],
that probably don’t take place in a physician visit discussing genetics and genomics.”
Although the participants felt the services provided by genetic counselors are important,
they shared that some physicians ordered genetic tests themselves and did not involve
genetic counselors.

Genetic Testing
Qualitative data revealed that genetic testing is being done by providers from a
variety of disciplines. Genetic testing was ordered for oncology patients, in labor and
delivery for fetal demise, in pediatrics, and for adults with symptoms of rare diseases.
One participant noted that testing is now more available, “I think for us in cancer care. . .
we have just started doing genetic testing here at the campus. . . I think it’s opened up
more doors for our community to be able to participate in testing. . .” Labor and delivery
nurses shared a different perspective, “So, genetic studies are not done very often.
Medicaid won’t pay for them which is a large population that we have and the doctor’s
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let them know [that test results are] . . . going to take like three months to come back and
most likely it will not give you any answers.”
Several participants indicated that most of their knowledge was from either
personal experience or a friend’s experience with genetic testing, not from their
baccalaureate nursing program. One participant, who underwent genetic testing herself
for a rare disease, stated, “. . . it took eight years. . . . the Mayo Clinic decided to do
genetic testing and they found that we had this neurological disorder and that’s [genetic
testing] the only thing that diagnosed us [participant and sister].” Another participant
discussed a friend and coworker’s experience of having her daughter tested due to
development delays. Both participants’ personal experience or friends’ experiences led
these nurses to seek out more genomic information and continuing education.

Support
Discussions of organizational support in the focus groups suggested that
promotion of genomic integration existed but there was a lack of knowledge about what
specific support was needed. “They’re [hospital leadership] all supportive. I think
they’re all inquisitive about what it entails.” One participant felt that physicians were
supportive but was unsure of how her nurse manager felt about genomics. This nurse
stated, “I mean our physicians work with us about it [genetics] and our surgical techs. . . I
have never and I’ve never seen anyone even talk to our boss [about genetics], so I don’t
know.” One participant illustrated organizational support for genomics by saying that
policies were in place to prevent discrimination in hiring those with genetic conditions.
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The lack of conversations about genomics, support for genomics, and mentorship from
nurse managers warrants further exploration.

Barriers
Knowledge, support, and costs were identified multiple times in both focus
groups as barriers to the utilization of genomics in nursing practice. Participants felt they
needed knowledge to explain genomics, answer questions, and speak with confidence to
patients and families about genomics. One participant stated, “Barriers to being able to
properly educate patients…nurses [don’t] . . . fully understand the process . . . we aren’t
actually doing anything except filling out a form.” All focus group participants expressed
the need for more continuing education as well as grant support for education and
research. One nurse stated, “[It’s] just lack of education. Maybe we could have some
mandatory education through our clinical unit educator to help us understand.” Another
said, “I would like more continuing education opportunities.”
Cost was viewed as a barrier to genomic testing because of the expense of testing
(in addition to already high health care costs), the potential lack of coverage for testing by
insurance companies, and the possibility of testing results providing no answers regarding
the cause of a condition. “Cost, because it’s probably going to be one of the first things
they [patients] ask,” illustrated these nurses’ concerns about the costs of testing,
insurance coverage for testing, and the ability to answer questions about testing for their
patients. One participant shared, “First of all, they have to understand what’s going on . .
.” She went on to explain that she felt it is hard for patients to understand they may have
to pay for an expensive test which may not provide any answers.
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Discussion
Results of this study support previous research findings indicating gaps between
genomic education and the application of genomics in nursing practice still exist. While
over 75% of participants had a baccalaureate degree in nursing, only 34% reported
learning about genomics and only 8% had a genomics course in their nursing program.
Data illustrates a lack of genomic content in nursing curricula and the importance of
genomic continuing education and attending genomic themed conferences/sessions.
Themes identified in the qualitative component of this study reaffirmed
knowledge and application deficits identified in the quantitative survey. Participants felt
that genomic knowledge is needed and important; but that barriers exist in providing
genomic-competent care to their patients. The quantitative survey’s findings of “Little to
no comfort” in obtaining a family history was confirmed in the focus group discussions.
In the focus groups, most participants expressed that they only asked about the patient’s
history. This may explain the lack of experience in identifying “red flags” in patients for
genetic testing among the participants.
The focus groups also illustrated that while nursing administration and nurse
managers may support genomics, there was a lack of understanding about what that
support should entail. Few participants shared the inclusion of genomic education in
their current position, mirroring the survey findings that 90% of participants felt that
there was little to no emphasis on genomic competencies in their hospital or on their unit.
These findings were also reflected in the lack of knowledge and support for genomics
barriers identified in the focus groups.
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Gaps continue to exist for both knowledge and use of genomics in nursing
practice. Calzone et al. (2013) found that participants in her study were unaware of the
Essentials of Genetic and Genomic Nursing:

Nursing Competencies, Curricula

Guidelines, and Outcome Indicators (ANA, 2009).

The results of this study were

consistent with Calzone et al. (2013) findings and was illustrated by the following focus
group statement, “I’m not aware of which bodies [that] verify competency …of people
providing services.” Finally, a lack of confidence in taking a family history was also
found in both components of this study. These findings align with the results of other
studies on nurses in practice, underscoring the need for and importance of continuing
education in genomics for nurses.

Strengths and Limitations
A strength of this investigation on genomic knowledge and application in nursing
practice was having a mixed method approach.

One hundred and fifty-one nurses,

working on a variety of specialty units, responded to the Qualtrics survey examining
attitudes, subjective norms, perceived behavioral control, and barriers in using genomics
in nursing practice. The quantitative results guided the development of focus group
questions to further explore these challenges. The qualitative findings added to the depth
of understanding about the attitudes, subjective norms, and perceived behavioral controls
of using genomics in nursing practice. Both sets of findings were consistent with the
results of previous studies on nurses’ knowledge and use of genomics in practice. Study
limitations included utilization of a convenience sample for both the quantitative and
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qualitative components of this investigation and that few nurses were able to participate
in the qualitative component due to scheduling.

Implications for Practice
The findings of this study revealed that nurses need genomic knowledge and
resources to answer patient and family questions, provide patient education, and deliver
genomic-competent care. Competency-based continuing education in genomics is key to
closing the education-practice gap. The participants in this study viewed support from
their peers, front-line nurse managers, and institutions as essential to increasing an
awareness and implementation of genomics in hospitals. Based on these findings, the
next steps are the following: initiate genomic education implementation studies, using
the TPB; develop an infrastructure to integrate and support the utilization of genomic
competencies in nursing practice; provide genomic resources for patients and families;
and promote delivery of genomic-competent care by nurses.
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CHAPTER V
SUMMARY, LIMITATIONS, AND RECOMMENDATIONS

Since completion of the Human Genome Project in 2003, genomic research has
generated increased knowledge, advanced the use of technology, led to the creation of
huge data bases and new bioinformatics applications, and expanded genomic applications
in healthcare (Aiello, 2017; Shendure, Findlay, & Snyder, 2019). Genomics impacts
patients and families across the healthcare continuum, including prevention, screening,
diagnosis, and treatment (Calzone et al., 2018). Across this continuum of care, nurses are
called to provide patient-centered care across a wide variety of settings, e.g., community,
hospitals, clinics, offices, and long-term care.

As the largest group of health care

professionals, nursing professionals must take responsibility to educate themselves about
genomics, achieve professional competencies, and apply genomics in patient care
(Jenkins, 2019). As genomic applications in healthcare continue to expand, nurses will
need to acquire new genomic knowledge and skills to provide genomic-competent care.
The Doctor of Philosophy degree program in Health Care Genetics in Clemson
University’s School of Nursing was designed as an interdisciplinary program to prepare
graduates to generate knowledge and develop theories focusing on genomics and health;
translate genomic knowledge from a variety of disciplines; formulate genomic-focused
health promotion, disease prevention and treatment strategies; and lead the development
and application of ethical guidelines and health policy in genomics (Clemson University,
School of Nursing, 2020). The HCG care model presented in Chapter I illustrated an
interdisciplinary approach to healthcare genetics and genomics.
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The central/core

concept, healthcare genetics/genomics, has linkages to genetics/genomics, education,
clinical testing and therapeutics, environment, and ethical, legal, and social implications
concepts. Guided by the HCG model, this dissertation explored the HCG model concepts
through scholarly works in Chapters II and III and a research study describing the
application of genomics in nursing practice in Chapter IV.

Chapter II
Tumor Profiling and Genomic Testing
Chapter II, Tumor Profiling, described and explored molecular profiling in
oncology. This chapter contributed to the development of genetics/genomics, education,
and clinical testing and therapeutics concepts in the HCG model. The chapter defined
single-gene biomarkers and multigene tests and their use as both prognostic and
predictive indicators. The chapter also presented use of the Kaplan-Meier survival curve
to evaluate the impact of interventions, such as oncologic treatments, on survival.
Chapter II also described how molecular testing is utilized in the field of oncology
to guide patient discussions on treatment recommendations. Breast cancer biomarkers
(ER, PR, HER2) are used in diagnostic evaluations and to guide treatment
recommendations.

Three breast cancer assays (Oncotype DX, MammaPrint,

Mammostrat), used in evaluating recurrence risk, offer information to help guide
discussions and decisions about breast cancer treatment plans.

In lung cancer, for

example, a genetic mutation in EGFR has an identified targeted therapy associated with
increased survival. Genetic tests to identify aberrations in the ALK and KRAS genes and
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measure expression of enzymes ERCC1 and RRM1 have also shown prognostic value in
lung cancer.
Colon cancer also has recognized biomarkers with treatment implications. For
example, KRAS mutations impact treatment recommendations for the addition of
monoclonal antibodies. As with breast cancer, several assays are utilized to predict
recurrence risk. Finally, a genomic test for prostate cancer can be used to guide treatment
decisions, e.g. surveillance versus radiation. In each of these examples, molecular testing
guides discussions and decisions about treatment options.

Limitations
With rapid growths in research and technology, the types and utilization of
biomarker and genomic testing has expanded. Since the publication of the Chapter II
manuscript in 2015, the number of genetic mutations used to guide treatment
recommendations and decisions, has increased significantly, as has access to expanded
multi-gene genomic tests.

For example, the manuscript described mutations in two

genes, EGFR and ALK, for lung cancer. In the 2020 National Comprehensive Cancer
Network (NCCN) guidelines, testing for seven different biomarkers, each associated with
an FDA approved therapy, is now recommended for advanced and metastatic lung
cancer.

Recommendations
Although Chapter II offered recommendations for clinical trial nurses, nurses in
all practice settings need genomic knowledge. Research on the utilization of genomic
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knowledge, testing, and the role of the nurse in testing across the care continuum is
important. Providing support for nurses to expand their knowledge of genomic profiling
beyond cancer to include other health conditions is key to enhancing the involvement of
nurses, as interdisciplinary team members, in discussions and decision-making with
patients and their families about diagnostic testing and treatment options.

Chapter III
Theory Application in Genomic Nursing Practice
Chapter III illustrates the importance and incorporation of the HCG model
concepts in genomic-competent nursing care, e.g., education, clinical testing and
therapeutics. The chapter introduces Ajzen’s Theory of Planned Behavior (TBP), the
constructs of attitude, subjective norms, and perceived behavioral control, and its
application to genomics in nursing practice (Ajzen, 1991, 2002).

Three exemplars

illustrate the use of genomic-competent nursing care for oncology patients and their
families. The first exemplar, family history, applies genomic competencies in eliciting,
analyzing, and applying family history in clinical testing and treatment as part of
genomic-competent nursing care.

The second exemplar, genomic testing, describes

typical approaches in testing for germline or somatic mutations in multiple genes, and the
clinical application of test results. The final exemplar, financial toxicity, explores the
impacts of social factors, e.g., testing and treatment costs and related access issues.
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Limitations
Nurses’ lack of genomic knowledge and skills impacts the utilization of genomics
in clinical practice. While these exemplars provided unique nursing applications, all
three were drawn from the field of oncology. Exemplars illustrating the use of genomics
in other nursing specialties would be beneficial.

Recommendations
Ajzen’s TPB constructs of attitude, subjective norms, and perceived behavioral
control guided the development of these oncology exemplars. These constructs could be
used to develop exemplars for other nursing specialties, e.g., maternal-child health,
pediatrics, and behavioral health. Ajzen’s constructs should be used in the development
of practice-transforming strategies addressing attitudes, subjective norms, and perceived
behavioral control. Developing strategies based on these constructs will promote the
implementation of genomic-competent care.

Chapter IV
Assessment of Genomics in Nursing Practice
Research reveals a gap between genomics in nursing education and nursing
practice (Aiello, 2017, Anderson et al., 2015, Calzone, et al., 2013; Calzone et al., 2012).
Chapter Four describes a mixed methods study of the application of genomics in nursing
practice. Ajzen’s TPB (1991, 2002) was used to guide this study. In the quantitative
component, a convenience sample of 151 registered nurses (RNs) at two Upstate South
Carolina hospitals completed a 27-item Qualtrics survey based on the TPB constructs
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(attitude, subjective norms, and perceived behavioral control). The quantitative survey
results guided the development of 10 open-ended focus group questions (qualitative
component). A focus group was held at each hospital to explore barriers to nurses
applying genomics in the care patients and their families.
The survey identified a lack of genomic education and knowledge that was
confirmed by focus group participants. Nurses in the focus groups discussed a need for
additional genomic education in order to answer patient and family questions; educate
patients and families about genetic testing and conditions and provide resources; and
provide genomic-competent care. Both the quantitative and qualitative arms of the study
revealed that nurses felt unprepared to take a three-generation family history. The survey
also found a lack of support by nurse leaders and healthcare organizations for genomic
education and application. Focus group discussions revealed that nursing leaders and
administrators value genomics but lacked an understanding of how to support nurses’
integration of genomics into practice. Insufficient knowledge, lack of administrative
support, and costs emerged as barriers to application of genomics in practice.

Limitations
Several study limitations were identified. First, the study participants were a
convenience sample of nurses from two upstate South Carolina hospitals. This sample
may not reflect the attitudes, subjective norms and behaviors of nurses from different
healthcare institutions and across specialties. While 16 nurses responded with an interest
to participate in a focus group, only seven nurses were able to attend due to challenges in
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scheduling a meeting time, based on their work schedules. Finally, both focus groups
were scheduled for one hour which may have limited discussion.

Recommendations
With continued gaps in genomic knowledge and its application, research is
needed to identify best practices to promote the dissemination of genomic knowledge and
skills in nursing education programs and continuing education for nurses. Using TPB
constructs (attitude, subjective norms, and perceived behavioral control), is key to
understanding the relationship between increased intention and actual use of genomics in
nursing practice.

Finally, implementation research is needed to develop effective

strategies that overcome barriers and bridge the education to practice gap.

Conclusions
In conclusion, a healthcare genetics/genomics model is useful in understanding
the relationships between genetics/genomics, education, clinical testing and therapeutics,
environmental influences, and ethical/legal/social implications.

Genomic education

about tumor profiling is essential for nursing involved in clinical trials and oncology.
Clinical exemplars illustrated the importance of genomic competencies in nursing.
Finally, a lack of genomic knowledge was found among practicing nurses, demonstrating
the importance of genomic education in nursing programs and in continuing education to
increase the use of genomic knowledge by nurses in practice.
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Dissertation Proposal Narrative
Elizabeth Hassen
ASSESSING THE FACILITATORS, BARRIERS, AND CHALLENGES OF
APPLYING GENOMICS IN NURSING CLINICAL PRACTICE
PRINCIPLE INVESTIGATOR: Elizabeth Hassen
TO BE CONDUCTED AT: Spartanburg Regional, AnMed Health, Bon Secours St.
Francis

Background & Significance:
Over the last decade there has been an exponential increase in genetic and
genomic knowledge, technologies, and research impacting the use of genomics across the
healthcare continuum and healthcare disciplines (ANA, 2009; Calzone, Jenkins, Nicol,
Skirton, Feero, & Green, 2013b). Currently, three important documents have been
published to advance genetics and genomics in nursing education with the goal to
incorporate into nursing clinical practice in the care of patients. The American
Association of Colleges of Nursing (AACN) published the Essentials of Baccalaureate
Education for Professional Nursing Practice (2008) and Essentials for Masters in
Nursing (2011) for nursing education. The American Nurses Association (ANA)
published the Essentials of genetic and genomic nursing: competencies, curricula
guidelines, and outcome indicators, 2nd ed (2009). These publications by the AACN
(2008) and the ANA (2009) have defined and guided genomic competency, including
conducting family health history, recognizing genetic risks, and recognizing relationships
of genetics and genomics to the health continuum. The competencies impact patient care
in areas of prevention, screening, diagnosis, and treatment of disease. Although Essential
competencies apply to the education of nurses with the implication for nurses to use in
the clinical setting, studies indicate the majority of nurses report their knowledge and
competency of genetics and genomics as low (Calzone, Jenkins, Culp, Bonham, &
Badzek, 2013a; Calzone et al., 2013b; Thompson & Brooks, 2011).
Other areas of significance include nursing education and the nursing workforce.
Various nursing organizations support competency integration into all entry levels of
nursing education programs. Kirk, Calzone, Arimori, and Tonkin (2011) recognized
barriers in their study on integration of genetics-genomics into nursing education: deficits
among educators, decreased awareness at the government level, limitations of resources,
lack of ‘patient voice’, and lack of evidence on outcomes. The International Society of
Nurses in Genetics (ISONG) and the American Nurses Association provide fundamental
support for the integration of genetics into health-care delivery. This is evidenced by
their support of research and the genomic competencies.
The nursing workforce was comprised of nearly 45% of nurses that were 50 or
older in 2008 and the average age reported in 2010 was 47 years old (Robert Wood
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Johnson Foundation, 2010). Considering the Human Genome Project was completed
2003, unless continuing education has been completed, many nurses lack genetic
knowledge. A workforce survey reports only 36% of nurses have a baccalaureate in
nursing (BSN) and less than 5% have a masters or doctorate (Buden, Zhong, Moulton, &
Cimiotti, 2013). This survey reveals the majority of nurses have an associate degree.
The growth of genetic and genomic research and discoveries is impacting the care and
treatment of patients in all aspects of the healthcare system. Genomics will continue to
have application in healthcare through personalized medicine.
Problem Statement:
Genomics is impacting screening recommendations, diagnosis, and treatment of
patients impacting nursing care. The problem is there remains a gap in knowledge and
application of genomics in nursing clinical practice (Calzone, Jenkins, Culp, Bonham, &
Badzek, 2013a; Calzone et al., 2013b; Thompson & Brooks, 2011). Kirk, Calzone,
Arimori, and Tonkin (2011) performed a small-scale international survey using openended questions to explore facilitators and barriers of genetic-genomic progress in the
respondent’s country. They found genetics-genomic competences were not fully
integrated into nursing education from the participating countries and were not reflected
in the standards for registration or licensure (Kirk et al., 2011). Kirk et al. (2011) also
noted challenges at both the national and international levels to produce a geneticgenomic competent nursing workforce. Other past researchers have also reported the
lack of genomic knowledge and competency in nursing clinical practice (Calzone et al.,
2013a; Calzone et al., 2013b; Rogers, Lizer, Doughty, Hayden, & Klein, 2017). The
literature discusses application for genomics and presents case studies on how to apply
genomics but no actually study exist that looks directly at translation of genomics from
the nurses’ perspective. Thompson and Brooks (2011) evaluated the implementation of
the Essentials using a survey, but about half of the respondents were nursing faculty.
Finally, Leach, Tonkin, Lancastle, and Kirk (2016) reported behavior change theories for
implementation of genomics into nursing practice, and presented a framework to inform
change, which includes the Theory of Planned Behavior (TPB) as the “core underpinning
theory” (p. 311). The authors also called for future research to look at the influence of
both environmental and social factors on the application of genomics in nursing clinical
practice (Leach et al., 2016).
Purpose of Study:
The purpose of this two-phase research study is to investigate the attitudes, social
norms, and perceived behavioral control that affect the intentions and use of genomics in
nursing clinical practice.
Research Questions:
1. What are the perceptions and experiences of licensed registered nurses working in
inpatient settings at upstate South Carolina community hospitals with application
of genomics?
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2. What are the perceptions and experiences of licensed registered nurses working in
inpatient settings at upstate South Carolina community hospitals with barriers to
application of genomics?
Contribution to healthcare genetics and nursing research:
The proposed study may contribute to the current research for clinical nurses’
perspectives on the barriers, facilitators, and challenges of applying genomics in nursing
clinical practice. Findings could guide implementation strategies and policy for
genomics in nursing practice.
Theoretical framework: Ajzen’s Theory of Planned Behavior

Figure 1. TPB theoretical framework. (Ajzen, 1991)

Specific Aims:
Specific Aim 1: Examine the attitudes that nurses have towards the use of genomics in
their nursing clinical practice.
Specific Aim 2: Examine the social norms including the encouragement, support, and
the feelings of their professional social network and colleagues toward the use of
genomics in nursing clinical practice.
Specific Aim 3: Identify the behavioral control, the facilitator and barriers, which exist
in applying genomics in nursing clinical practice.
Specific Aim 4: Identify the behavioral intentions for the use of genomic concepts in
nursing clinical practice.
PROCEDURE
Population and Sample:
The target population will consist of sample will consist of licensed registered
nurses currently working in the clinical setting. The sample for phase one will consist of
a minimum of 50 nurses completing the Qualtrics survey. A purposeful sample of 10 and
no more than 20 licensed registered nurses in South Carolina currently working in the
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inpatient clinical setting for the focus groups in phase two. Recruitment of nurses will be
from three local large community hospitals.
Eligibility requirements:
• ADN or BSN degree
• Not currently enrolled in school
• Work in an inpatient clinical setting
• Licensure in SC
• Not a travel nurse
Methodology:
Phase I, a Qualtrics survey (n=50) is to investigate the application of genomics
based on the constructs of the Theory of Planned Behavior (TPB) and the AACN’s
Essentials. The results from Qualtrics descriptive statistics and t-test results will be
utilized to guide the specific types of questions used in the second phase of the research.
Phase II, focus group methodology (n=10-15) further explores the positive and
negatives of the TPB constructs. Data collection will involve three focus groups held in
three different locations across the upstate of South Carolina to gather verbal data to ask
about the attitudes, socials norms, and perceived behavioral control towards the intention
of applying genomics in nursing clinical practice. Data analysis will employ NVivo, a
qualitative data analysis software, for content analysis of the verbal data for emergent
themes.
Demographic questions
1. Race/Ethnicity
2. Gender
3. Nursing degree level – ADN or BSN
4. Years of clinical experience
5. Specialty: Med-Surg, Cardiac, OB, Oncology
6. Did you have a genomics class
7. Did you learn about genomics in nursing school
Focus Group questions
Phenomenological open-ended questions for the focus groups will be guided by the
constructs of the Theory of Planned Behavior. Questions will consist of:
-Attitude
• How would you describe your attitude towards using genomics? What
experiences do you have with these competencies?
• Use of family history
• Identifying familial trends
• Pharmacogenomics
• Genetic testing
• Referrals for genetic testing
• What are your perceptions and experiences with the use of genomics in clinical
practice?
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•

What is your view on whether it is beneficial or harmful?

-Subjective norms
• What are your perceptions and experiences with manager/leadership support for
use of genomics?
• Discuss your perceptions and experiences with organizational support
demonstrated towards genomics?
• What are your perceptions and experiences with genomic practices or
competencies you or your peers use in practice?
-Perceived behavioral control
• What are your perceptions and experiences with genomic tools or resources
available?
• What are your perceptions and experiences with documentation tools available for
genomics?
• What are your perceptions and experiences with tools used for referrals for
genomics?
• What are your perceptions and experiences with barriers and challenges that
prevent you from utilizing genomics in practice?
Timeline for the Project:
Upon approval by Spartanburg Medical Center IRB and Clemson University IRB,
data collection will begin. Phase I survey will be distributed and open for 2 weeks.
Analysis will begin as soon as the survey is closed. Phase II focus group questions will
be revised. Focus groups planned to be held in June 2018 over a 2-week period.
Analysis of qualitative data using Nvivo will begin as soon as focus groups are
completed. Research will be submitted for publication, and presentation of research will
be made at Clemson University. Research will also be presented at health systems in
which research was done as requested, including Spartanburg Regional Nursing Research
Council. Abstract has been submitted to present data at International Society of Nurses
in Genetics (ISONG) in October 2018 based on research proposal.
Human Subjects Research:
Clemson University IRB and the HSSC e-IRB approval will be obtained. The
primary investigator has completed the required Collaborative IRB Training Initiative
(CITI) courses. There are no racial or ethnic limitations for the sample participants.
Risk to Subjects
There are minimal risks to the participating subjects involved in the research.
Informed consent for participation will include the purpose of study and any potential
risks and benefits of participation. Subjects will be informed that all information
obtained in the Qualtrics survey will remain anonymous and will not have any identifying
information. The responses will be secured in a file that only the principle investigator
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can access. Permission will be obtained by participants of focus groups to be video and
audio recorded for transcription purposes and will be signed prior to the start of each
focus group. In addition, confidentiality and privacy will be ensured.
Limitations:
While three local community clinical sites are utilized, they are all located in one
region of South Carolina.
Potential Benefit of the Reseach:
This research will inform and support future implementation of genomics into
nursing clinical practice.
References:
Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human
Decision Processes, 50(2), 179-211
American Association of Colleges of Nursing. (2008). Essentials of Baccalaureate
Education for Professional Nursing Practice. Washington, DC.
American Nurses Association. (2009). Essentials of Genetic and Genomic Nursing:
Competencies, Curricula Guidelines, and Outcome Indicators. (2nd ed.). Silver
Spring, MD.
Budden, J. S., Zhong, E. H., Moulton, P., & Cimiotti, J. P. (2013). Highlights of the
national workforce survey of registered nurses. Journal of Nursing Regulation,
4(2), 5-14.
Calzone, K. A., Jenkins, J., Culp, S., Bonham Jr, V. L., & Badzek, L. (2013a). National
nursing workforce survey of nursing attitudes, knowledge and practice in
genomics. Personalized Medicine, 10(7), 719-728.
Calzone, K. A., Jenkins, J., Nicol, N., Skirton, H., Feero, W. G., & Green, E. D. (2013b).
Relevance of genomics to healthcare and nursing practice. Journal of Nursing
Scholarship, 45(1), 1-2.
Calzone, K. A., Jenkins, J., Yates, J., Cusack, G., Wallen, G. R., Liewehr, D. J., &
McBride, C. (2012). Survey of nursing integration of genomics into nursing
practice. Journal of Nursing Scholarship, 44(4), 428-436.
Commission on Collegiate Nursing Education. Standards for Accreditation of
Baccalaureate and Graduate Degree Nursing Programs. 2014 [cited 2015
2/24/2015]; Available from: http://www.aacn.nche.edu/ccneaccreditation/Procedures.pdf.

97

Jenkins, J. & Calzone, K. (2007). Establishing the Essential Nursing Competencies for
Genetics and Genomics. Journal of Nursing Scholarship, 39 (1), 10-16.
Kirk, M., Calzone, K., Arimori, N., & Tonkin, E. (2011). Genetics‐Genomics
Competencies and Nursing Regulation. Journal of Nursing Scholarship, 43(2),
107-116.
Leach, V., Tonkin, E., Lancastle, D., & Kirk, M. (2016). A strategy for implementing
genomics into nursing practice informed by three behaviour change theories.
International Journal of Nursing Practice, 22(3), 307-315.
Rogers, M. A., Lizer, S., Doughty, A., Hayden, B., & Klein, C. J. (2017). Expanding
RN Scope of Knowledge—Genetics/Genomics: The New Frontier. Journal for
Nurses in Professional Development, 33(2), 56-63.
Thompson, H. J., & Brooks, M. V. (2011). Genetics and genomics in nursing:
evaluating essentials implementation. Nurse Education Today, 31(6), 623-627.

98

Appendix B
IRB Approval Form

99

100

101

Appendix C
Consent Phase I
Information about Being in a Research Study
Clemson University
Assessment of Genomics in Clinical Nursing Practice
Description of the Study and Your Part in It
Elizabeth C Hassen, Ph.D.(c), RN, OCN is a Ph.D. student at Clemson University
conducting this study with the guidance of Rosanne Pruitt, dissertation chair. The
purpose of this two-phase research study is to investigate the barriers and use of
genomics in nursing clinical practice.
Your participation will involve taking a 27 question Likert-type scale questionnaire, six
demographic questions and an additional 21 questions to gather data about the use of
genomics in your clinical nursing practice. It will take you about 20 minutes to complete
the survey. At the conclusion of the survey, it will provide further instructions should
you want to participate in a follow up focus group. The focus group will take about an
hour of your time to discuss your experiences with using genomics in your clinical
nursing practice.
Risks and Discomforts
There is minimal risk or discomfort to you as a result of participation in this research
study. Sometimes when answering questions about an unfamiliar subject, it is possible
for one to experience anxiety or discomfort, especially when questions are respective to
your employment. Elizabeth Hassen has been a nurse for 16 years and can address
concerns at the time of the focus group.
Possible Benefits
There are no direct benefits from participation in this study. However, this research can
help us to understand the barriers and experiences of using genomics in clinical nursing
practice which will allow us to bring education and implementation strategies back to
nurses to increase genomics application in clinical nursing practice.
Incentives
For those participating in the focus groups, one participant will be selected at random to
receive a membership to a nursing organization of their choice for a year.
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Protection of Privacy and Confidentiality
The surveys will be completed in Qualtrics without identifiable information. For those
participating in focus groups, video and audio recording will be done during the group
discussion for translation and transcription of data for analysis. Participants’ identity will
be coded to protect their privacy. Some comments, de-identified, could be included as
quotations to emphasize certain points of the data. Storage of video and audio recordings
and will be included in the folder of data and consent forms stored in a cabinet in a
locked office. These will be appropriately destroyed after five years.
The results of this study may be published in scientific journals, professional
publications, or educational presentations; however, no individual participant information
will be identified.
Choosing to Be in the Study
You do not have to be in this study. You may choose to take part in Phase I, the
Qualtrics survey, and not to take part in Phase II, focus groups. You may choose to stop
taking part in the research study at any time. Your participation in the research and
follow-up focus groups will not be affected in any way if you decide not to be in the
study or to stop taking part in the study.
Contact Information
If you have any questions or concerns about this study or if any problems arise, please
contact Elizabeth Hassen at Clemson University at 864-764-4797.
If you have any questions or concerns about your rights in this research study, please
contact the Clemson University Office of Research Compliance (ORC) at 864-656-0636
or irb@clemson.edu. If you are outside of the Upstate South Carolina area, please use
the ORC’s toll-free number, 866-297-3071. The Clemson IRB is a group of people who
independently review research. The Clemson IRB will not be able to answer some studyspecific questions. However, you may contact the Clemson IRB if the research staff
cannot be reached or if you wish to speak with someone other than the research staff.
Consent
By participating in the study, you indicate that you have read the information
written above, are at least 18 years of age, been allowed to ask any questions, and
are voluntarily choosing to take part in this research. You do not give up any legal
rights by taking part in this research study.
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Appendix D
Survey Questions
Preliminary Research Survey
Demographic questions:
1. Race/Ethnicity
__ Caucasian __ African American __Hispanic __Other
2. Gender
__ Male
__ Female
3. Nursing degree level
__ ADN
__ BSN
4. Years of clinical experience _____________
5. Specialty:
__ Med-Surg __ Cardiac
__ OB __ Oncology __ Peds
__ Other
6. Did you have a stand-alone genomics class in nursing school?
__ Yes __ No
Research Questions:
7. Have you learned about genomics in nursing school or another setting?
__ Nursing school
__ Another setting
__ Neither
Text box: What type of setting?

8. How would you rate your attitude towards using genomics in the clinical setting?
Positive 5 – 4 – 3 – 2 – 1 Negative
What experiences do you have with the following genetic American Association of
Colleges of Nurses (AACN) Essential competencies?
9. How would you rate your comfort level with obtaining a family history of a
disease/disorder?
A Great Deal – Much – Somewhat – Little – Never
10. How many generations do you seek information on when taking a family history?
1–2–3–4–5
11. Do you take a 3-degrees (generations) of family history?
Yes - No
12. Do you have any experience with identifying ‘red flags’ of inherited family
diseases/disorders?
A Great Deal – Much – Somewhat – Little – Never
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13. Do you have any experience using genetics for appropriately identifying
medications for your patient (pharmacogenomics)?
A Great Deal – Much – Somewhat – Little – Never
14. I have _____________ knowledge and experience with genetic testing in the
clinical setting?
A Great Deal – Much – Somewhat – Little – Never
(Text box: Please describe)
15. Do patients ask you for information about genetic testing?
A Great Deal – Much – Somewhat – Little – Never
16. I have _____________ experience identifying when patient should be referred for
genetic testing?
A Great Deal – Much – Somewhat – Little – Never
17. How would you rate your perceptions and experiences with the use of genomics
in clinical practice?
Positive 5 – 4 – 3 – 2 – 1 Negative
(Text box: Please describe an example either positive or negative)
18. Do you feel the genomic information provided to patients is beneficial to patients
or overwhelming?
Beneficial – Overwhelming – No opinion
19. Does your manager/leadership support the use of genomics in your practice?
A Great Deal – Much – Somewhat – Little – Never
20. Does your clinical organization demonstrate support towards genomics?
A Great Deal – Much – Somewhat – Little – Never
21. Does your hospital or unit competencies include genomic concepts?
A Great Deal – Much – Somewhat – Little – Never
22. Do your peers utilize genomic practices or competencies in their clinical practice?
A Great Deal – Much – Somewhat – Little – Never
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23. Do you currently use genomic concepts and/or services in your nursing clinical
practice?
Yes – No
(Text box: If so, which concepts and/or services)
24. Have you utilized any genomic tools or resources that are available?
On Unit – Online – Both – Neither
(Text box: If so, which tools or resources?)
25. Have you used any documentation tools available for genomics?
Yes – No
(Text box: If so, which tools?)
26. Have you spoken to a care provider or physician regarding a high-risk patient?
Yes – No
(Text box: If so, which concepts?)
27. What are the barriers and challenges that prevent you from utilizing genomics in
practice?
Text box
28. Text Box: Additional comments: Please share any other perceptions or
experiences with genomics that you would like to add that has not been asked
here.
If you would be willing to participate in a focus group to further explain this research,
please email me at ehassen@clemson.edu. The focus group will allow discussion to
expand on the above concepts to identify use and barriers of genomics in patient care.
The focus group would last approximately 1 hour in length with appetizers and drinks
provided.
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Appendix E
Consent Phase II
Information about Being in a Research Study
Clemson University
Assessment of Genomics in Clinical Nursing Practice
Description of the Study and Your Part in It
Elizabeth C Hassen, Ph.D.(c), RN, OCN is a Ph.D. student at Clemson University
conducting this study with the guidance of Rosanne Pruitt, dissertation chair. The
purpose of this two-phase research study is to investigate the barriers and use of
genomics in nursing clinical practice.
Your participation will involve taking a 27 question Likert-type scale questionnaire, six
demographic questions and an additional 21 questions to gather data about the use of
genomics in your clinical nursing practice. It will take you about 20 minutes to complete
the survey. At the conclusion of the survey, it will provide further instructions should
you want to participate in a follow up focus group. The focus group will take about an
hour of your time to discuss your experiences with using genomics in your clinical
nursing practice.
Risks and Discomforts
There is minimal risk or discomfort to you as a result of participation in this research
study. Sometimes when answering questions about an unfamiliar subject, it is possible
for one to experience anxiety or discomfort, especially when questions are respective to
your employment. Elizabeth Hassen has been a nurse for 16 years and can address
concerns prior to the focus group beginning.
Possible Benefits
There are no direct benefits from participation in this study. However, this research can
help us to understand the barriers and experiences of using genomics in clinical nursing
practice which will allow us to bring education and implementation strategies back to
nurses to increase genomics application in clinical nursing practice.
Incentives
For those participating in the focus groups, one participant will be selected at random to
receive a membership to a nursing organization of their choice for a year.
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Protection of Privacy and Confidentiality
The surveys will be completed in Qualtrics without identifiable information. For those
participating in focus groups, video and audio recording will be done during the group
discussion for translation and transcription of data for analysis. Participants’ identity will
be coded to protect their privacy. Some comments, de-identified, could be included as
quotations to emphasize certain points of the data. Storage of video and audio recordings
and will be included in the folder of data and consent forms stored in a cabinet in a
locked office. These will be appropriately destroyed after five years.
The results of this study may be published in scientific journals, professional
publications, or educational presentations; however, no individual participant information
will be identified.
Choosing to Be in the Study
You do not have to be in this study. You may choose to take part in Phase I, the
Qualtrics survey, and not to take part in Phase II, focus groups. You may choose to stop
taking part in the research study at any time. Your participation in the research and
follow-up focus groups will not be affected in any way if you decide not to be in the
study or to stop taking part in the study.
Contact Information
If you have any questions or concerns about this study or if any problems arise, please
contact Elizabeth Hassen at Clemson University at 864-764-4797.
If you have any questions or concerns about your rights in this research study, please
contact the Clemson University Office of Research Compliance (ORC) at 864-656-0636
or irb@clemson.edu. If you are outside of the Upstate South Carolina area, please use
the ORC’s toll-free number, 866-297-3071. The Clemson IRB is a group of people who
independently review research. The Clemson IRB will not be able to answer some studyspecific questions. However, you may contact the Clemson IRB if the research staff
cannot be reached or if you wish to speak with someone other than the research staff.
Consent
By participating in the study, you indicate that you have read the information
written above, are at least 18 years of age, been allowed to ask any questions, and
are voluntarily choosing to take part in this research. You do not give up any legal
rights by taking part in this research study.
I have read this form and have been allowed to ask any questions I might have. I
agree to participate in the study. I agree to have my conversation audio taped and
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photographs to be taken and used, without identifying information, in posters and
journal articles.
Participant’s Printed signature: ____________________________________
Participant’s signature: ___________________________________________

Date: _________________
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Appendix F
Focus Group Interview Questions
Phenomenological open-ended questions for the focus groups will be guided by the
constructs of the Theory of Planned Behavior and will be guided based on the
preliminary survey results. Questions will consist of:
-Attitude
• How would you describe your attitude towards using genomics?
• Do you have experience with the use of these genomic competencies in clinical
practice?
• Use of family history
• Identifying familial trends
• Pharmacogenomics
• Genetic testing
• Referrals for genetic testing
• Do you feel that genomic information is beneficial for patients?

-Subjective norms
• What are your perceptions and experiences with manager/leadership support for
use of genomics?
• Discuss your perceptions and experiences with organizational support
demonstrated towards genomics?
• What are your perceptions and experiences with genomic practices or
competencies you or your peers use in practice?
-Perceived behavioral control
• What are your perceptions and experiences with genomic tools or resources
available? Have you completed any continuing education on genomics?
• Do you use documentation tools available for genomics? Are they within your
electronic medical system?
• What are your perceptions and experiences with tools used for referrals for
genomics? Have you spoken to a physician about high risk patients?
• What do you see as barriers and challenges that prevent you from utilizing
genomics in practice? Knowledge? Lack of support? Others?
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